SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE: Form 990, tax year 2017

View the entire original 990 at ProPublica ↗

Organization: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (EIN 51-0197108)
Tax period: 2017-07-01 to 2018-06-30
Filed: 2019-05-14
IRS object ID: 201911349349306321
Schema version: 2017v2.3
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule B
Schedule C
Schedule D
Schedule F
Schedule G
Schedule J
Schedule K
Schedule L
Schedule O
Schedule R

Return header ReturnHeader

Field	Value	IRS element (for citing)
Return	2019-05-14T13:23:59-05:00	ReturnTs
Tax Period End	2018-06-30	TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

Preparer Firm Name PreparerFirmName

Field	Value	IRS element (for citing)
Business Name Line1	ERNST & YOUNG US LLP	BusinessNameLine1Txt

Preparer US Address PreparerUSAddress

Field	Value	IRS element (for citing)
Address Line1	4365 EXECUTIVE DRIVE STE 1600	AddressLine1Txt
City	SAN DIEGO	CityNm
State Abbreviation	CA	StateAbbreviationCd
ZIP	92121	ZIPCd

Field	Value	IRS element (for citing)
Return Type	990	ReturnTypeCd
Tax Period Begin	2017-07-01	TaxPeriodBeginDt

Filer Filer

Field	Value	IRS element (for citing)
EIN	510197108	EIN

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	SANFORD BURNHAM PREBYS MEDICAL DISCOVERY	BusinessNameLine1Txt
Business Name Line2	INSTITUTE	BusinessNameLine2Txt

Field	Value	IRS element (for citing)
In Care Of	% Louis Coffman	InCareOfNm
Business Name Control	SANF	BusinessNameControlTxt
Phone	8586463100	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	10901 NORTH TORREY PINES ROAD	AddressLine1Txt
City	LA JOLLA	CityNm
State Abbreviation	CA	StateAbbreviationCd
ZIP	92037	ZIPCd

Business Officer BusinessOfficerGrp

Field	Value	IRS element (for citing)
Person	LOUIS COFFMAN	PersonNm
Person Title	CAO/CFO	PersonTitleTxt
Phone	8586463100	PhoneNum
Signature	2019-05-13	SignatureDt
Discuss With Paid Preparer	Yes (true)	DiscussWithPaidPreparerInd

Preparer Person PreparerPersonGrp

Field	Value	IRS element (for citing)
Preparer Person	JOCELYNE MILLER	PreparerPersonNm
PTIN	P00634378	PTIN
Phone	8585357200	PhoneNum

Filing Security Information FilingSecurityInformation

IP Address IPAddress

Field	Value	IRS element (for citing)
I Pv4 Address	164.57.159.254	IPv4AddressTxt

Field	Value	IRS element (for citing)
Federal Original Submission Id	33008120191345000003	FederalOriginalSubmissionId
Federal Original Submission Id	2019-05-14	FederalOriginalSubmissionIdDt
Filing License Type	P	FilingLicenseTypeCd
At Submission Creation Device Id	CBBDC42840D8014E8353DD16D453BA683ED30307	AtSubmissionCreationDeviceId
At Submission Filing Device Id	C8EB7D7F4A43AD7C11A3CC780D94EAED606DA475	AtSubmissionFilingDeviceId

Field	Value	IRS element (for citing)
Tax	2017	TaxYr
Build TS	2019-02-21 02:37:17Z	BuildTS

Form 990 IRS990

Field	Value	IRS element (for citing)
Principal Officer	KRISTIINA VUORI	PrincipalOfficerNm

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	10901 NORTH TORREY PINES ROAD	AddressLine1Txt
City	LA JOLLA	CityNm
State Abbreviation	CA	StateAbbreviationCd
ZIP	92037	ZIPCd

Field	Value	IRS element (for citing)
Gross Receipts	$239,215,538	GrossReceiptsAmt
Group Return For Affiliates	false	GroupReturnForAffiliatesInd
Organization501c3	Yes (X)	Organization501c3Ind
Website Address	WWW.SBPDISCOVERY.ORG	WebsiteAddressTxt
Type Of Organization Corp	Yes (X)	TypeOfOrganizationCorpInd
Formation	1976	FormationYr
Legal Domicile State	CA	LegalDomicileStateCd
Activity Or Mission	SEE SCHEDULE O	ActivityOrMissionDesc
Voting Members Governing Body	16	VotingMembersGoverningBodyCnt
Voting Members Independent	15	VotingMembersIndependentCnt
Total Employee	969	TotalEmployeeCnt
Total Volunteers	22	TotalVolunteersCnt
Total Gross UBI	$2,574,121	TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm	$80,364	NetUnrelatedBusTxblIncmAmt
PY Contributions Grants	$121,777,889	PYContributionsGrantsAmt
CY Contributions Grants	$113,630,164	CYContributionsGrantsAmt
PY Program Service Revenue	$1,413,894	PYProgramServiceRevenueAmt
CY Program Service Revenue	$1,300,446	CYProgramServiceRevenueAmt
PY Investment Income	$5,628,894	PYInvestmentIncomeAmt
CY Investment Income	$6,744,651	CYInvestmentIncomeAmt
PY Other Revenue	$5,353,488	PYOtherRevenueAmt
CY Other Revenue	$3,651,490	CYOtherRevenueAmt
PY Total Revenue	$134,174,165	PYTotalRevenueAmt
CY Total Revenue	$125,326,751	CYTotalRevenueAmt
PY Grants And Similar Paid	$0	PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid	$0	CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members	$0	PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members	$0	CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid	$79,341,143	PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid	$76,269,756	CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns	$0	PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns	$0	CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense	$1,399,236	CYTotalFundraisingExpenseAmt
PY Other Expenses	$67,504,171	PYOtherExpensesAmt
CY Other Expenses	$67,249,608	CYOtherExpensesAmt
PY Total Expenses	$146,845,314	PYTotalExpensesAmt
CY Total Expenses	$143,519,364	CYTotalExpensesAmt
PY Revenues Less Expenses	-$12,671,149	PYRevenuesLessExpensesAmt
CY Revenues Less Expenses	-$18,192,613	CYRevenuesLessExpensesAmt
Total Assets BOY	$482,051,570	TotalAssetsBOYAmt
Total Assets EOY	$430,760,547	TotalAssetsEOYAmt
Total Liabilities BOY	$174,862,590	TotalLiabilitiesBOYAmt
Total Liabilities EOY	$149,095,244	TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY	$307,188,980	NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY	$281,665,303	NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part III	Yes (X)	InfoInScheduleOPartIIIInd
Mission	SEE SCHEDULE O	MissionDesc
Significant New Program Srvc	false	SignificantNewProgramSrvcInd
Significant Change	false	SignificantChangeInd
Expense	$118,498,212	ExpenseAmt
Grant	$0	GrantAmt
Revenue	$1,632,086	RevenueAmt
Desc	SEE SCHEDULE O	Desc
Total Program Service Expenses	$118,498,212	TotalProgramServiceExpensesAmt
Described In Section501c3	Yes (true)	DescribedInSection501c3Ind
Schedule B Required	Yes (true)	ScheduleBRequiredInd
Political Campaign Acty	false	PoliticalCampaignActyInd
Lobbying Activities	Yes (true)	LobbyingActivitiesInd
Subject To Proxy Tax	false	SubjectToProxyTaxInd
Donor Advised Fund	false	DonorAdvisedFundInd
Conservation Easements	false	ConservationEasementsInd
Collections Of Art	false	CollectionsOfArtInd
Credit Counseling	false	CreditCounselingInd
Temp Or Permanent Endowments	Yes (true)	TempOrPermanentEndowmentsInd
Report Land Building Equipment	Yes (true)	ReportLandBuildingEquipmentInd
Report Investments Other Sec	false	ReportInvestmentsOtherSecInd
Report Program Related Invst	false	ReportProgramRelatedInvstInd
Report Other Assets	false	ReportOtherAssetsInd
Report Other Liabilities	false	ReportOtherLiabilitiesInd
Include FIN48 Footnote	Yes (true)	IncludeFIN48FootnoteInd
Independent Audit Fincl Stmt	Yes (true)	IndependentAuditFinclStmtInd
Consolidated Audit Fincl Stmt	false	ConsolidatedAuditFinclStmtInd
School Operating	false	SchoolOperatingInd
Foreign Office	Yes (true)	ForeignOfficeInd
Foreign Activities	Yes (true)	ForeignActivitiesInd
More Than5000 K To Org	false	MoreThan5000KToOrgInd
More Than5000 K To Individuals	false	MoreThan5000KToIndividualsInd
Professional Fundraising	false	ProfessionalFundraisingInd
Fundraising Activities	Yes (true)	FundraisingActivitiesInd
Gaming Activities	false	GamingActivitiesInd
Operate Hospital	false	OperateHospitalInd
Grants To Organizations	false	GrantsToOrganizationsInd
Grants To Individuals	false	GrantsToIndividualsInd
Schedule J Required	Yes (true)	ScheduleJRequiredInd
Tax Exempt Bonds	Yes (true)	TaxExemptBondsInd
Invest Tax Exempt Bonds	false	InvestTaxExemptBondsInd
Escrow Account	false	EscrowAccountInd
On Behalf Of Issuer	false	OnBehalfOfIssuerInd
Engaged In Excess Benefit Trans	false	EngagedInExcessBenefitTransInd
PY Excess Benefit Trans	false	PYExcessBenefitTransInd
Loan Outstanding	Yes (true)	LoanOutstandingInd
Grant To Related Person	false	GrantToRelatedPersonInd
Business Rln With Org Mem	false	BusinessRlnWithOrgMemInd
Business Rln With Fam Mem	false	BusinessRlnWithFamMemInd
Business Rln With Officer Ent	false	BusinessRlnWithOfficerEntInd
Deductible Non Cash Contri	false	DeductibleNonCashContriInd
Deductible Art Contribution	false	DeductibleArtContributionInd
Terminate Operations	false	TerminateOperationsInd
Partial Liquidation	false	PartialLiquidationInd
Disregarded Entity	false	DisregardedEntityInd
Related Entity	Yes (true)	RelatedEntityInd
Related Organization Ctrl Ent	Yes (true)	RelatedOrganizationCtrlEntInd
Transaction With Control Ent	false	TransactionWithControlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org	false	TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp	false	ActivitiesConductedPrtshpInd
Schedule O Required	Yes (true)	ScheduleORequiredInd
IRP Document	211	IRPDocumentCnt
IRP Document W2 G	0	IRPDocumentW2GCnt
Backup Wthld Compliance	Yes (true)	BackupWthldComplianceInd
Employee	969	EmployeeCnt
Employment Tax Returns Filed	Yes (true)	EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over Limit	Yes (true)	UnrelatedBusIncmOverLimitInd
Form990 T Filed	Yes (true)	Form990TFiledInd
Foreign Financial Account	false	ForeignFinancialAccountInd
Prohibited Tax Shelter Trans	false	ProhibitedTaxShelterTransInd
Taxable Party Notification	false	TaxablePartyNotificationInd
Nondeductible Contributions	false	NondeductibleContributionsInd
Quid Pro Quo Contributions	Yes (true)	QuidProQuoContributionsInd
Quid Pro Quo Contri Discl	Yes (true)	QuidProQuoContriDisclInd
Form8282 Property Disposed Of	false	Form8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft Cntrct	false	RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct	false	PayPremiumsPrsnlBnftCntrctInd
Indoor Tanning Services	false	IndoorTanningServicesInd
Info In Schedule O Part VI	Yes (X)	InfoInScheduleOPartVIInd
Governing Body Voting Members	16	GoverningBodyVotingMembersCnt
Independent Voting Member	15	IndependentVotingMemberCnt
Family Or Business Rln	false	FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties	false	DelegationOfMgmtDutiesInd
Change To Org Documents	false	ChangeToOrgDocumentsInd
Material Diversion Or Misuse	false	MaterialDiversionOrMisuseInd
Members Or Stockholders	false	MembersOrStockholdersInd
Election Of Board Members	false	ElectionOfBoardMembersInd
Decisions Subject To Approva	false	DecisionsSubjectToApprovaInd
Minutes Of Governing Body	Yes (true)	MinutesOfGoverningBodyInd
Minutes Of Committees	Yes (true)	MinutesOfCommitteesInd
Officer Mailing Address	false	OfficerMailingAddressInd
Local Chapters	false	LocalChaptersInd
Form990 Provided To Gvrn Body	Yes (true)	Form990ProvidedToGvrnBodyInd
Conflict Of Interest Policy	Yes (true)	ConflictOfInterestPolicyInd
Annual Disclosure Covered Prsn	Yes (true)	AnnualDisclosureCoveredPrsnInd
Regular Monitoring Enfrc	Yes (true)	RegularMonitoringEnfrcInd
Whistleblower Policy	Yes (true)	WhistleblowerPolicyInd
Document Retention Policy	Yes (true)	DocumentRetentionPolicyInd
Compensation Process CEO	Yes (true)	CompensationProcessCEOInd
Compensation Process Other	Yes (true)	CompensationProcessOtherInd
Investment In Joint Venture	false	InvestmentInJointVentureInd
States Where Copy Of Return Is Fld	AL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AK	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CO	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	DC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	FL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	GA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	IL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	ME	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MD	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NJ	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NM	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	ND	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OK	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	PA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	RI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	SC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	TN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	UT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	VA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WV	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WI	StatesWhereCopyOfReturnIsFldCd
Upon Request	Yes (X)	UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Field	Value	IRS element (for citing)
Person	Louis Coffman	PersonNm
Phone	8586463100	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	10901 N TORREY PINES RD	AddressLine1Txt
City	LA JOLLA	CityNm
State Abbreviation	CA	StateAbbreviationCd
ZIP	92037	ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (31 entries)

TitleTitleTxt	Average Hours Per WeekAverageHoursPerWeekRt	Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt	Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd	OfficerOfficerInd	Reportable Comp From OrgReportableCompFromOrgAmt	Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt	Other CompensationOtherCompensationAmt	Highest Compensated EmployeeHighestCompensatedEmployeeInd
KRISTIINA VUORI MD PHD
PRESIDENT	50.0	0.0	Yes (X)	Yes (X)	$969,097	$0	$343,074
DOUGLAS OBENSHAIN
TRUSTEE	1.0	0.0	Yes (X)		$0	$0	$0
DAVID DOWN
TRUSTEE	1.0	0.0	Yes (X)		$0	$0	$0
WILLIAM GERHART
TRUSTEE	1.0	0.0	Yes (X)		$0	$0	$0
LUDER WHITLOCK
TRUSTEE (PART YEAR)	1.0	0.0	Yes (X)		$0	$0	$0
LORENZO BERHO
TRUSTEE (PART YEAR)	1.0	0.0	Yes (X)		$0	$0	$0
WAINWRIGHT FISHBURN
TRUSTEE (PART YEAR)	1.0	0.0	Yes (X)		$0	$0	$0
ALAN GLEICHER
TRUSTEE	1.0	0.0	Yes (X)		$0	$0	$0
JEANNE HERBERGER
TRUSTEE	1.0	0.0	Yes (X)		$0	$0	$0
DONALD JERNIGAN
TRUSTEE (PART YEAR)	1.0	0.0	Yes (X)		$0	$0	$0
EDWARD SCHULAK
TRUSTEE (PART YEAR)	1.0	0.0	Yes (X)		$0	$0	$0
STUART TANZ
TRUSTEE	1.0	0.0	Yes (X)		$0	$0	$0
CAROL GALLAGHER
TRUSTEE (PART YEAR)	1.0	0.0	Yes (X)		$0	$0	$0
GREG LUCIER
TRUSTEE (PART YEAR)	1.0	0.0	Yes (X)		$0	$0	$0
JAMES JARDON
TRUSTEE	1.0	0.0	Yes (X)		$0	$0	$0
DONALD ROSENBERG
TRUSTEE	1.0	0.0	Yes (X)		$0	$0	$0
JAMES MYERS
TRUSTEE	1.0	0.0	Yes (X)		$0	$0	$0
KAZUMI SHIOSAKI
TRUSTEE	1.0	0.0	Yes (X)		$0	$0	$0
PETER SEIDLER
TRUSTEE	1.0	0.0	Yes (X)		$0	$0	$0
ANNA BARKER
TRUSTEE	1.0	0.0	Yes (X)		$0	$0	$0
DANIEL EPSTEIN
TRUSTEE	1.0	0.0	Yes (X)		$0	$0	$0
PERRY NISEN MD PHD
CEO (PART YEAR)	50.0	0.0	Yes (X)	Yes (X)	$1,205,646	$0	-$431,901
HENRY NORDOFF
CHAIRMAN	1.0	0.0	Yes (X)	Yes (X)	$0	$0	$0
JAMES BLAIR
VICE CHAIRMAN	1.0	0.0	Yes (X)	Yes (X)	$0	$0	$0
KNOX BELL
CORPORATE SECRETARY	2.0	0.0		Yes (X)	$0	$0	$0
GARY CHESSUM
CFO	50.0	0.0		Yes (X)	$376,444	$0	$54,366
GARTH POWIS PHD
CENTER DIRECTOR	50.0	0.0			$504,423	$0	$44,881	Yes (X)
DANIEL KELLY MD
CENTER DIR/SCI DIR AT LK NONA	50.0	0.0			$602,402	$0	$44,466	Yes (X)
EDWARD LEWANDOWSKI
PROFESSOR	50.0	0.0			$652,124	$0	$53,856	Yes (X)
CARL WARE PHD
CENTER DIRECTOR, IIDC	50.0	0.0			$393,349	$0	$44,954	Yes (X)
MICHAEL JACKSON PHD
DRUG DISCOVERY & DEV, SR VP	50.0	0.0			$388,597	$0	$54,059	Yes (X)

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	$5,092,082	TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org	$0	TotReportableCompRltdOrgAmt
Total Other Compensation	$207,755	TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K	154	IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed	false	FormerOfcrEmployeesListedInd
Total Comp Greater Than150 K	Yes (true)	TotalCompGreaterThan150KInd
Compensation From Other Srcs	false	CompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (5 entries)

Address Line1ContractorAddress/USAddress/AddressLine1Txt	CityContractorAddress/USAddress/CityNm	State AbbreviationContractorAddress/USAddress/StateAbbreviationCd	ZIPContractorAddress/USAddress/ZIPCd	ServicesServicesDesc	CompensationCompensationAmt
DLA PIPER US LLP
401 B STREET 1700	SAN DIEGO	CA	92101	LEGAL SERVICES	$569,166
Adimab LLC partnership
7 Lucent Drive Lebanon	Lebanon	NH	03766	Lab/Research SVCS	$456,519
Deloitte Touche LLP
655 WEST BROADWAY SUITE 700	San Diego	CA	92101	AUDIT SERVICES	$417,295
Allied Universal Security - Partner
PO Box 31001-2374	Pasadena	CA	91110	Security Services	$420,476
Wilson Sonsini Goodrich
PO BOX 742866	Los Angeles	CA	90074	LEGAL SERVICES	$248,000

Field	Value	IRS element (for citing)
Cntrct Rcvd Greater Than100 K	8	CntrctRcvdGreaterThan100KCnt
Fundraising	$604,273	FundraisingAmt
Government Grants	$70,305,568	GovernmentGrantsAmt
All Other Contributions	$42,720,323	AllOtherContributionsAmt
Noncash Contributions	$0	NoncashContributionsAmt
Total Contributions	$113,630,164	TotalContributionsAmt

Program Service Revenue ProgramServiceRevenueGrp

Field	Value	IRS element (for citing)
Desc	Shared Services Revenue	Desc
Business	541990	BusinessCd
Total Revenue Column	$1,300,446	TotalRevenueColumnAmt
Related Or Exempt Func Income	$1,300,446	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$0	ExclusionAmt

Field	Value	IRS element (for citing)
Total Program Service Revenue	$1,300,446	TotalProgramServiceRevenueAmt

Investment Income InvestmentIncomeGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$4,373,835	TotalRevenueColumnAmt
Unrelated Business Revenue	$213	UnrelatedBusinessRevenueAmt
Exclusion	$4,373,622	ExclusionAmt

Incm From Invest Bond Proceeds IncmFromInvestBondProceedsGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt

Royalties Revenue RoyaltiesRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$956,483	TotalRevenueColumnAmt
Exclusion	$956,483	ExclusionAmt

Gross Rents GrossRentsGrp

Field	Value	IRS element (for citing)
Real	$16,460	RealAmt

Rental Income Or Loss RentalIncomeOrLossGrp

Field	Value	IRS element (for citing)
Real	$16,460	RealAmt
Personal	$0	PersonalAmt

Net Rental Income Or Loss NetRentalIncomeOrLossGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$16,460	TotalRevenueColumnAmt
Exclusion	$16,460	ExclusionAmt

Gross Amount Sales Assets GrossAmountSalesAssetsGrp

Field	Value	IRS element (for citing)
Securities	$115,980,102	SecuritiesAmt

Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp

Field	Value	IRS element (for citing)
Securities	$113,609,286	SecuritiesAmt

Gain Or Loss GainOrLossGrp

Field	Value	IRS element (for citing)
Securities	$2,370,816	SecuritiesAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$2,370,816	TotalRevenueColumnAmt
Exclusion	$2,370,816	ExclusionAmt

Field	Value	IRS element (for citing)
Fundraising Gross Income	$52,500	FundraisingGrossIncomeAmt
Contri Rpt Fundraising Event	$604,273	ContriRptFundraisingEventAmt
Fundraising Direct Expenses	$279,501	FundraisingDirectExpensesAmt

Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp

Field	Value	IRS element (for citing)
Total Revenue Column	-$227,001	TotalRevenueColumnAmt
Exclusion	-$227,001	ExclusionAmt

Field	Value	IRS element (for citing)
Gaming Gross Income	$0	GamingGrossIncomeAmt
Gaming Direct Expenses	$0	GamingDirectExpensesAmt

Net Income From Gaming NetIncomeFromGamingGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt

Field	Value	IRS element (for citing)
Gross Sales Of Inventory	$0	GrossSalesOfInventoryAmt
Cost Of Goods Sold	$0	CostOfGoodsSoldAmt

Net Income Or Loss NetIncomeOrLossGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt

Other Revenue Misc OtherRevenueMiscGrp (3 entries)

DescDesc	BusinessBusinessCd	Total Revenue ColumnTotalRevenueColumnAmt	Related Or Exempt Func IncomeRelatedOrExemptFuncIncomeAmt	Unrelated Business RevenueUnrelatedBusinessRevenueAmt	ExclusionExclusionAmt
Research	541700	$2,573,908	$0	$2,573,908	$0
OTHER RESEARCH SUPPORT	541990	$137,307	$137,307	$0	$0
SALE OF REAGENTS	541990	$41,263	$41,263	$0	$0

Miscellaneous Revenue MiscellaneousRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$153,070	TotalRevenueColumnAmt
Related Or Exempt Func Income	$153,070	RelatedOrExemptFuncIncomeAmt
Exclusion	$0	ExclusionAmt

Field	Value	IRS element (for citing)
Other Revenue Total	$2,905,548	OtherRevenueTotalAmt

Total Revenue TotalRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$125,326,751	TotalRevenueColumnAmt
Related Or Exempt Func Income	$1,632,086	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$2,574,121	UnrelatedBusinessRevenueAmt
Exclusion	$7,490,380	ExclusionAmt

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt

Grants To Domestic Individuals GrantsToDomesticIndividualsGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt

Foreign Grants ForeignGrantsGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt

Benefits To Members BenefitsToMembersGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

Field	Value	IRS element (for citing)
Total	$2,696,931	TotalAmt
Program Services	$158,377	ProgramServicesAmt
Management And General	$2,538,554	ManagementAndGeneralAmt

Comp Disqual Persons CompDisqualPersonsGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

Field	Value	IRS element (for citing)
Total	$57,562,490	TotalAmt
Program Services	$46,896,620	ProgramServicesAmt
Management And General	$9,887,060	ManagementAndGeneralAmt
Fundraising	$778,810	FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

Field	Value	IRS element (for citing)
Total	$3,771,796	TotalAmt
Program Services	$3,082,013	ProgramServicesAmt
Management And General	$638,088	ManagementAndGeneralAmt
Fundraising	$51,695	FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

Field	Value	IRS element (for citing)
Total	$8,779,133	TotalAmt
Program Services	$7,344,977	ProgramServicesAmt
Management And General	$1,359,065	ManagementAndGeneralAmt
Fundraising	$75,091	FundraisingAmt

Payroll Taxes PayrollTaxesGrp

Field	Value	IRS element (for citing)
Total	$3,459,406	TotalAmt
Program Services	$2,712,977	ProgramServicesAmt
Management And General	$693,443	ManagementAndGeneralAmt
Fundraising	$52,986	FundraisingAmt

Fees For Services Management FeesForServicesManagementGrp

Field	Value	IRS element (for citing)
Total	$1,721,171	TotalAmt
Program Services	$867,152	ProgramServicesAmt
Management And General	$845,514	ManagementAndGeneralAmt
Fundraising	$8,505	FundraisingAmt

Fees For Services Legal FeesForServicesLegalGrp

Field	Value	IRS element (for citing)
Total	$1,147,792	TotalAmt
Program Services	$38,754	ProgramServicesAmt
Management And General	$1,109,038	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Fees For Services Accounting FeesForServicesAccountingGrp

Field	Value	IRS element (for citing)
Total	$384,853	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$384,853	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Fees For Services Lobbying FeesForServicesLobbyingGrp

Field	Value	IRS element (for citing)
Total	$1,060	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$1,060	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Fees For Services Prof Fundraising FeesForServicesProfFundraising

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Fundraising	$0	FundraisingAmt

Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp

Field	Value	IRS element (for citing)
Total	$15,536	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$15,536	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Fees For Services Other FeesForServicesOtherGrp

Field	Value	IRS element (for citing)
Total	$1,274,282	TotalAmt
Program Services	$561,743	ProgramServicesAmt
Management And General	$701,480	ManagementAndGeneralAmt
Fundraising	$11,059	FundraisingAmt

Advertising AdvertisingGrp

Field	Value	IRS element (for citing)
Total	$51,701	TotalAmt
Program Services	$2,625	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$49,076	FundraisingAmt

Office Expenses OfficeExpensesGrp

Field	Value	IRS element (for citing)
Total	$7,794,564	TotalAmt
Program Services	$6,985,035	ProgramServicesAmt
Management And General	$762,007	ManagementAndGeneralAmt
Fundraising	$47,522	FundraisingAmt

Information Technology InformationTechnologyGrp

Field	Value	IRS element (for citing)
Total	$1,437,250	TotalAmt
Program Services	$1,066,233	ProgramServicesAmt
Management And General	$340,494	ManagementAndGeneralAmt
Fundraising	$30,523	FundraisingAmt

Royalties RoyaltiesGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Occupancy OccupancyGrp

Field	Value	IRS element (for citing)
Total	$13,737,146	TotalAmt
Program Services	$12,162,746	ProgramServicesAmt
Management And General	$1,488,145	ManagementAndGeneralAmt
Fundraising	$86,255	FundraisingAmt

Travel TravelGrp

Field	Value	IRS element (for citing)
Total	$720,200	TotalAmt
Program Services	$639,575	ProgramServicesAmt
Management And General	$72,121	ManagementAndGeneralAmt
Fundraising	$8,504	FundraisingAmt

Pymt Travel Entrtnmnt Pub Ofcl PymtTravelEntrtnmntPubOfclGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Conferences Meetings ConferencesMeetingsGrp

Field	Value	IRS element (for citing)
Total	$1,202,241	TotalAmt
Program Services	$949,079	ProgramServicesAmt
Management And General	$224,784	ManagementAndGeneralAmt
Fundraising	$28,378	FundraisingAmt

Interest InterestGrp

Field	Value	IRS element (for citing)
Total	$2,044,147	TotalAmt
Program Services	$1,853,837	ProgramServicesAmt
Management And General	$173,344	ManagementAndGeneralAmt
Fundraising	$16,966	FundraisingAmt

Payments To Affiliates PaymentsToAffiliatesGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Depreciation Depletion DepreciationDepletionGrp

Field	Value	IRS element (for citing)
Total	$13,919,772	TotalAmt
Program Services	$12,560,655	ProgramServicesAmt
Management And General	$1,294,091	ManagementAndGeneralAmt
Fundraising	$65,026	FundraisingAmt

Insurance InsuranceGrp

Field	Value	IRS element (for citing)
Total	$22,857	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$22,857	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Other Expenses OtherExpensesGrp (4 entries)

DescDesc	TotalTotalAmt	Program ServicesProgramServicesAmt	Management And GeneralManagementAndGeneralAmt	FundraisingFundraisingAmt
RESEARCH SUPPLIES & SERVICES	$13,215,854	$13,215,854	$0	$0
SCIENTIFIC COLLABORATIONS	$7,157,418	$7,157,418	$0	$0
BAD DEBT	$576,628	$0	$576,628	$0
CONTRIBUTED ASSETS	$387,651	$0	$387,651	$0

All Other Expenses AllOtherExpensesGrp

Field	Value	IRS element (for citing)
Total	$437,485	TotalAmt
Program Services	$242,542	ProgramServicesAmt
Management And General	$106,103	ManagementAndGeneralAmt
Fundraising	$88,840	FundraisingAmt

Total Functional Expenses TotalFunctionalExpensesGrp

Field	Value	IRS element (for citing)
Total	$143,519,364	TotalAmt
Program Services	$118,498,212	ProgramServicesAmt
Management And General	$23,621,916	ManagementAndGeneralAmt
Fundraising	$1,399,236	FundraisingAmt

Total Joint Costs TotalJointCostsGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

Field	Value	IRS element (for citing)
BOY	$4,468,804	BOYAmt
EOY	$5,792,608	EOYAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

Field	Value	IRS element (for citing)
BOY	$21,504,849	BOYAmt
EOY	$13,539,386	EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$36,509,300	BOYAmt
EOY	$9,531,085	EOYAmt

Accounts Receivable AccountsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$854,298	BOYAmt
EOY	$345,952	EOYAmt

Receivables From Officers Etc ReceivablesFromOfficersEtcGrp

Field	Value	IRS element (for citing)
BOY	$1,137,581	BOYAmt
EOY	$911,111	EOYAmt

Rcvbl From Disqualified Prsn RcvblFromDisqualifiedPrsnGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Oth Notes Loans Receivable Net OthNotesLoansReceivableNetGrp

Field	Value	IRS element (for citing)
BOY	$1,160,303	BOYAmt
EOY	$693,912	EOYAmt

Inventories For Sale Or Use InventoriesForSaleOrUseGrp

Field	Value	IRS element (for citing)
BOY	$177,124	BOYAmt
EOY	$145,372	EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

Field	Value	IRS element (for citing)
BOY	$6,858,015	BOYAmt
EOY	$6,819,615	EOYAmt

Field	Value	IRS element (for citing)
Land Bldg Equip Cost Or Other Bss	$305,401,482	LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec	$180,215,660	LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

Field	Value	IRS element (for citing)
BOY	$134,501,742	BOYAmt
EOY	$125,185,822	EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

Field	Value	IRS element (for citing)
BOY	$256,843,206	BOYAmt
EOY	$247,437,682	EOYAmt

Investments Other Securities InvestmentsOtherSecuritiesGrp

Field	Value	IRS element (for citing)
BOY	$15,556,694	BOYAmt
EOY	$18,047,415	EOYAmt

Investments Program Related InvestmentsProgramRelatedGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Intangible Assets IntangibleAssetsGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Other Assets Total OtherAssetsTotalGrp

Field	Value	IRS element (for citing)
BOY	$2,479,654	BOYAmt
EOY	$2,310,587	EOYAmt

Total Assets TotalAssetsGrp

Field	Value	IRS element (for citing)
BOY	$482,051,570	BOYAmt
EOY	$430,760,547	EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

Field	Value	IRS element (for citing)
BOY	$16,961,878	BOYAmt
EOY	$16,125,390	EOYAmt

Grants Payable GrantsPayableGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Deferred Revenue DeferredRevenueGrp

Field	Value	IRS element (for citing)
BOY	$96,699,380	BOYAmt
EOY	$75,065,356	EOYAmt

Tax Exempt Bond Liabilities TaxExemptBondLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$61,201,332	BOYAmt
EOY	$57,904,498	EOYAmt

Escrow Account Liability EscrowAccountLiabilityGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Loans From Officers Directors LoansFromOfficersDirectorsGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Mortg Notes Pybl Scrd Invst Prop MortgNotesPyblScrdInvstPropGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Unsecured Notes Loans Payable UnsecuredNotesLoansPayableGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Other Liabilities OtherLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Total Liabilities TotalLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$174,862,590	BOYAmt
EOY	$149,095,244	EOYAmt

Field	Value	IRS element (for citing)
Organization Follows SFAS117	Yes (X)	OrganizationFollowsSFAS117Ind

Unrestricted Net Assets UnrestrictedNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$180,035,528	BOYAmt
EOY	$199,720,438	EOYAmt

Temporarily Rstr Net Assets TemporarilyRstrNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$113,099,936	BOYAmt
EOY	$67,889,349	EOYAmt

Permanently Rstr Net Assets PermanentlyRstrNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$14,053,516	BOYAmt
EOY	$14,055,516	EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$307,188,980	BOYAmt
EOY	$281,665,303	EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$482,051,570	BOYAmt
EOY	$430,760,547	EOYAmt

Field	Value	IRS element (for citing)
Info In Schedule O Part XI	Yes (X)	InfoInScheduleOPartXIInd
Reconcilation Revenue Expnss	-$18,192,613	ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst	$3,556,936	NetUnrlzdGainsLossesInvstAmt
Donated Services And Use Fclts	$0	DonatedServicesAndUseFcltsAmt
Investment Expense	$0	InvestmentExpenseAmt
Prior Period Adjustments	$0	PriorPeriodAdjustmentsAmt
Other Changes In Net Assets	-$10,888,000	OtherChangesInNetAssetsAmt
Method Of Accounting Accrual	Yes (X)	MethodOfAccountingAccrualInd
Accountant Compile Or Review	false	AccountantCompileOrReviewInd
FS Audited	Yes (true)	FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

Field	Value	IRS element (for citing)
Separate Basis Fincl Stmt	Yes (X)	SeparateBasisFinclStmtInd

Field	Value	IRS element (for citing)
Audit Committee	Yes (true)	AuditCommitteeInd
Federal Grant Audit Required	Yes (true)	FederalGrantAuditRequiredInd
Federal Grant Audit Performed	Yes (true)	FederalGrantAuditPerformedInd

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Public Organization170	Yes (X)	PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$143,361,221	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$240,798,040	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$112,703,072	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$121,777,889	CurrentTaxYearMinus1YearAmt
Current Tax Year	$113,630,164	CurrentTaxYearAmt
Total	$732,270,386	TotalAmt

Tax Rev Levied Orgnztnl Bnft170 TaxRevLeviedOrgnztnlBnft170Grp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Govt Furn Srvc Fclts Vl170 GovtFurnSrvcFcltsVl170Grp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$143,361,221	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$240,798,040	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$112,703,072	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$121,777,889	CurrentTaxYearMinus1YearAmt
Current Tax Year	$113,630,164	CurrentTaxYearAmt
Total	$732,270,386	TotalAmt

Field	Value	IRS element (for citing)
Substantial Contributors Tot	$80,507,105	SubstantialContributorsTotAmt
Public Support Total170	$651,763,281	PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$4,044,153	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$6,992,391	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$5,532,193	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$6,303,751	CurrentTaxYearMinus1YearAmt
Current Tax Year	$5,346,565	CurrentTaxYearAmt
Total	$28,219,053	TotalAmt

Unrelated Business Net Incm170 UnrelatedBusinessNetIncm170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$195,599	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$160,548	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$52,137	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$281,883	CurrentTaxYearMinus1YearAmt
Current Tax Year	$48,551	CurrentTaxYearAmt
Total	$738,718	TotalAmt

Other Income170 OtherIncome170Grp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Field	Value	IRS element (for citing)
Total Support	$761,228,157	TotalSupportAmt
Gross Receipts Rltd Activities	$9,117,752	GrossReceiptsRltdActivitiesAmt
Public Support CY170	0.85620	PublicSupportCY170Pct
Public Support PY170	0.86141	PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170	Yes (X)	ThirtyThrPctSuprtTestsCY170Ind

Schedule B IRS990ScheduleB

Schedule C IRS990ScheduleC

Field	Value	IRS element (for citing)
Total Grassroots Lobbying		TotalGrassrootsLobbyingGrp
Total Direct Lobbying		TotalDirectLobbyingGrp
Total Lobbying Expend		TotalLobbyingExpendGrp
Other Exempt Purpose Expend		OtherExemptPurposeExpendGrp
Total Exempt Purpose Expend		TotalExemptPurposeExpendGrp
Lobbying Nontaxable Amount		LobbyingNontaxableAmountGrp
Grassroots Nontaxable		GrassrootsNontaxableGrp
Tot Lbbyng Grassroot Mns Non Tx		TotLbbyngGrassrootMnsNonTxGrp
Tot Lbby Expend Mns Lbbyng Non Tx		TotLbbyExpendMnsLbbyngNonTxGrp
Volunteers	false	VolunteersInd
Paid Staff Or Management	false	PaidStaffOrManagementInd
Media Advertisements	false	MediaAdvertisementsInd
Media Advertisements	$0	MediaAdvertisementsAmt
Mailings Members	false	MailingsMembersInd
Mailings Members	$0	MailingsMembersAmt
Publications Or Broadcast	false	PublicationsOrBroadcastInd
Publications Or Broadcast	$0	PublicationsOrBroadcastAmt
Grants Other Organizations	false	GrantsOtherOrganizationsInd
Grants Other Organizations	$0	GrantsOtherOrganizationsAmt
Direct Contact Legislators	false	DirectContactLegislatorsInd
Direct Contact Legislators	$0	DirectContactLegislatorsAmt
Rallies Demonstrations	false	RalliesDemonstrationsInd
Rallies Demonstrations	$0	RalliesDemonstrationsAmt
Other Activities	Yes (true)	OtherActivitiesInd
Other Activities	$1,060	OtherActivitiesAmt
Total Lobbying Expenditures	$1,060	TotalLobbyingExpendituresAmt
Not Described Section501c3	false	NotDescribedSection501c3Ind

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	SCHEDULE C, PART II-B, LINE 1I	FormAndLineReferenceDesc
Explanation	OTHER ACTIVITIES DUES TO RESEARCH AND BIOMEDICAL ORGANIZATIONS, A PORTION OF WHICH ARE CONSIDERED LOBBYING. THE INSTITUTE UTILIZES ATLANTIC STRATEGIES GROUP, LLC FOR REPRESENTATION IN WASHINGTON DC, TO INVESTIGATE AND SEEK POTENTIAL FEDERAL RESEARCH FUNDING OPPORTUNITIES OUTSIDE THE TRADITIONAL NIH PROCESS. THE INSTITUTE CONTRACTS WITH CAPITAL INSIGHT AND ASSOCIATES FOR REPRESENTATION IN TALLAHASSEE, FL, TO INVESTIGATE AND SEEK POTENTIAL STATE RESEARCH FUNDING OPPORTUNITIES.	ExplanationTxt

Schedule D IRS990ScheduleD

Field	Value	IRS element (for citing)
Art Public Exhibition Amounts		ArtPublicExhibitionAmountsGrp
Held Works Art		HeldWorksArtGrp

CY Endwmt Fund CYEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$28,681,314	BeginningYearBalanceAmt
Contributions	$502,000	ContributionsAmt
Investment Earnings Or Losses	$1,841,686	InvestmentEarningsOrLossesAmt
Other Expenditures	$1,225,257	OtherExpendituresAmt
End Year Balance	$29,799,743	EndYearBalanceAmt

CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$25,987,641	BeginningYearBalanceAmt
Contributions	$530,336	ContributionsAmt
Investment Earnings Or Losses	$3,395,420	InvestmentEarningsOrLossesAmt
Other Expenditures	$1,232,083	OtherExpendituresAmt
End Year Balance	$28,681,314	EndYearBalanceAmt

CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$26,693,919	BeginningYearBalanceAmt
Contributions	$510,067	ContributionsAmt
Investment Earnings Or Losses	-$3,125	InvestmentEarningsOrLossesAmt
Other Expenditures	$1,213,220	OtherExpendituresAmt
End Year Balance	$25,987,641	EndYearBalanceAmt

CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$26,870,514	BeginningYearBalanceAmt
Contributions	$920,000	ContributionsAmt
Investment Earnings Or Losses	$36,749	InvestmentEarningsOrLossesAmt
Other Expenditures	$1,133,344	OtherExpendituresAmt
End Year Balance	$26,693,919	EndYearBalanceAmt

CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$22,805,011	BeginningYearBalanceAmt
Contributions	$1,310,000	ContributionsAmt
Investment Earnings Or Losses	$3,778,222	InvestmentEarningsOrLossesAmt
Other Expenditures	$1,022,719	OtherExpendituresAmt
End Year Balance	$26,870,514	EndYearBalanceAmt

Field	Value	IRS element (for citing)
Board Designated Balance EOY	0.45760	BoardDesignatedBalanceEOYPct
Prmnnt Endowment Balance EOY	0.47130	PrmnntEndowmentBalanceEOYPct
Term Endowment Balance EOY	0.07110	TermEndowmentBalanceEOYPct
Endowments Held Unrelated Org	false	EndowmentsHeldUnrelatedOrgInd
Endowments Held Related Org	false	EndowmentsHeldRelatedOrgInd

Land LandGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$25,793,087	OtherCostOrOtherBasisAmt
Book Value	$25,793,087	BookValueAmt

Buildings BuildingsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$166,746,637	OtherCostOrOtherBasisAmt
Depreciation	$85,510,125	DepreciationAmt
Book Value	$81,236,512	BookValueAmt

Field	Value	IRS element (for citing)
Leasehold Improvements		LeaseholdImprovementsGrp

Equipment EquipmentGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$112,279,614	OtherCostOrOtherBasisAmt
Depreciation	$94,705,535	DepreciationAmt
Book Value	$17,574,079	BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$582,144	OtherCostOrOtherBasisAmt
Book Value	$582,144	BookValueAmt

Field	Value	IRS element (for citing)
Total Book Value Land Buildings	$125,185,822	TotalBookValueLandBuildingsAmt
Federal Income Tax Liability	$0	FederalIncomeTaxLiabilityAmt
Total Liability	$0	TotalLiabilityAmt
Footnote Text	Yes (X)	FootnoteTextInd
Total Rev Etc Audited Fincl Stmt	$128,867,000	TotalRevEtcAuditedFinclStmtAmt
Net Unrealized Gains Invst	$3,556,935	NetUnrealizedGainsInvstAmt
Revenue Not Reported	$3,556,935	RevenueNotReportedAmt
Revenue Subtotal	$125,310,065	RevenueSubtotalAmt
Investment Expenses Not Incld	$15,536	InvestmentExpensesNotIncldAmt
Other Revenues Not Included	$1,150	OtherRevenuesNotIncludedAmt
Revenue Not Reported Fincl Stmt	$16,686	RevenueNotReportedFinclStmtAmt
Total Revenue Per Form990	$125,326,751	TotalRevenuePerForm990Amt
Tot Expns Etc Audited Fincl Stmt	$143,504,000	TotExpnsEtcAuditedFinclStmtAmt
Other Expenses Included	$0	OtherExpensesIncludedAmt
Expenses Not Reported	$0	ExpensesNotReportedAmt
Expenses Subtotal	$143,504,000	ExpensesSubtotalAmt
Investment Expenses Not Incld2	$15,536	InvestmentExpensesNotIncld2Amt
Other Expenses Not Included	-$172	OtherExpensesNotIncludedAmt
Expenses Not Rpt Fincl Stmt	$15,364	ExpensesNotRptFinclStmtAmt
Total Expenses Per Form990	$143,519,364	TotalExpensesPerForm990Amt

Supplemental Information Detail SupplementalInformationDetail (4 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
SCHEDULE D, PART V, LINE 4	INTENDED USES OF THE ORGANIZATION'S ENDOWMENT FUNDS THE INSTITUTE'S ENDOWMENT FUNDS ARE ESTABLISHED FOR VARIOUS PURPOSES: SCIENTIFIC RESEARCH, CEO CHAIR, PRESIDENTIAL CHAIR, CANCER AND NEUROSCIENCE LEADERSHIP CHAIRS, AND UNRESTRICTED AS TO INCOME.
SCHEDULE D, PART X, LINE 2	FIN 48 (ASC 740) FOOTNOTE THE INSTITUTE HAS NO MATERIAL DEFERRED TAX ASSETS OR DEFERRED TAX LIABILITIES RECORDED AS OF JUNE 30, 2018 AND 2017. THE INSTITUTE DID NOT RECOGNIZE A CHANGE IN LIABILITY FOR UNRECOGNIZED TAX BENEFITS (THE DIFFERENCE BETWEEN A TAX POSITION TAKEN, OR EXPECTED TO BE TAKEN, IN A TAX RETURN AND THE BENEFIT RECOGNIZED AND MEASURED IN THE FINANCIAL STATEMENTS). THERE WERE NO LIABILITIES FOR UNRECOGNIZED TAX BENEFITS AT JUNE 30, 2018 AND 2017.
SCHEDULE D, PART XI, LINE 2D	ROUNDING - 1,150
SCHEDULE D, PART XII, LINE 4B	ROUNDING - (172)

Schedule F IRS990ScheduleF

Account Activities Outside US AccountActivitiesOutsideUSGrp (9 entries)

RegionRegionTxt	EmployeeEmployeeCnt	Type Of Activities ConductedTypeOfActivitiesConductedTxt	Specific Services ProvidedSpecificServicesProvidedTxt	Region Total ExpendituresRegionTotalExpendituresAmt
Europe (Including Iceland and Greenland)	44	Program Services	See Part V	$213,056
East Asia and the Pacific	25	Program Services	See Part V	$68,100
North America	1	Program Services	See Part V	$2,323
South Asia	3	Program Services	See Part V	$14,358
Middle East and North Africa	2	Program Services	See Part V	$17,375
Russia and the Newly Independent States	1	Program Services	See Part V	$3,163
South America	6	Program Services	See Part V	$11,864
Sub-Saharan Africa	1	Program Services	See Part V	$11,050
Central America and the Caribbean		Investments		$3,250,000

Field	Value	IRS element (for citing)
Subtotal Employees	83	SubtotalEmployeesCnt
Total Employee	83	TotalEmployeeCnt
Subtotal Spent	$3,591,289	SubtotalSpentAmt
Total Spent	$3,591,289	TotalSpentAmt
Transfer To Foreign Corp	Yes (true)	TransferToForeignCorpInd
Interest In Foreign Trust	false	InterestInForeignTrustInd
Foreign Corp Ownership	Yes (true)	ForeignCorpOwnershipInd
Passive Foreign Investmest Co	Yes (true)	PassiveForeignInvestmestCoInd
Foreign Partnership	false	ForeignPartnershipInd
Boycott Countries	false	BoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail (3 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
SCHEDULE F, PART I, LINE 3	PROGRAM SERVICE ACTIVITIES SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE DOES NOT MAINTAIN ONGOING OPERATIONS IN FOREIGN JURISDICTIONS. HOWEVER, THE INSTITUTE'S SCIENTISTS DO TRAVEL TO VARIOUS SCIENTIFIC CONFERENCES IN OTHER COUNTRIES TO SHARE THE INSTITUTE'S SCIENTIFIC DISCOVERIES AND TO LEARN FROM OTHER SCIENTISTS ACROSS THE WORLD.
SCHEDULE F, PART I, LINE 3, COLUMN E	TYPE OF SERVICE SPECIFIC PROGRAM SERVICE ACTIVITY IN ALL REGIONS IS AGENTS ATTENDING AND/OR SPEAKING AT SCIENTIFIC CONFERENCES AND COLLABORATIONS.
SCHEDULE F, PART I, LINE 3, COLUMN F	ACCOUNTING METHOD THE ACCRUAL METHOD OF ACCOUNTING WAS USED TO DETERMINE THE AMOUNTS IN PART I, LINE 3, COLUMN F.

Schedule G IRS990ScheduleG

Fundraiser Activity Info FundraiserActivityInfoGrp (2 entries)

ActivityActivityTxt	Fundraiser Control Of FundsFundraiserControlOfFundsInd
ED GILLENWATERS
CONSULTING	false
BLAIR BLUM PARTNERS
CONSULTING	false

Fundraising Event Information FundraisingEventInformationGrp

Field	Value	IRS element (for citing)
Event1	GALA	Event1Nm
Gross Receipts Event1	$484,563	GrossReceiptsEvent1Amt
Charitable Contri Event1	$462,063	CharitableContriEvent1Amt
Gross Revenue Event1	$22,500	GrossRevenueEvent1Amt
Food And Beverage Event1	$53,108	FoodAndBeverageEvent1Amt
Entertainment Event1	$43,584	EntertainmentEvent1Amt
Other Direct Expenses Event1	$43,732	OtherDirectExpensesEvent1Amt
Event2	BRING IT	Event2Nm
Gross Receipts Event2	$172,210	GrossReceiptsEvent2Amt
Charitable Contri Event2	$142,210	CharitableContriEvent2Amt
Gross Revenue Event2	$30,000	GrossRevenueEvent2Amt
Rent Facility Costs Event2	$6,426	RentFacilityCostsEvent2Amt
Food And Beverage Event2	$52,050	FoodAndBeverageEvent2Amt
Entertainment Event2	$2,000	EntertainmentEvent2Amt
Other Direct Expenses Event2	$78,601	OtherDirectExpensesEvent2Amt
Other Events Total	0	OtherEventsTotalCnt
Gross Receipts Total	$656,773	GrossReceiptsTotalAmt
Charitable Contributions Tot	$604,273	CharitableContributionsTotAmt
Gross Revenue Total Events	$52,500	GrossRevenueTotalEventsAmt
Rent Fclty Costs Total Events	$6,426	RentFcltyCostsTotalEventsAmt
Food And Beverage Total Events	$105,158	FoodAndBeverageTotalEventsAmt
Entertainment Total Events	$45,584	EntertainmentTotalEventsAmt
Oth Direct Expnss Total Events	$122,333	OthDirectExpnssTotalEventsAmt
Direct Expense Summary Events	$279,501	DirectExpenseSummaryEventsAmt
Net Income Summary	-$227,001	NetIncomeSummaryAmt

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
First Class Or Charter Travel	Yes (X)	FirstClassOrCharterTravelInd
Club Dues Or Fees	Yes (X)	ClubDuesOrFeesInd
Written Policy Ref T And E Expnss	Yes (true)	WrittenPolicyRefTAndEExpnssInd
Substantiation Required	Yes (true)	SubstantiationRequiredInd
Compensation Committee	Yes (X)	CompensationCommitteeInd
Independent Consultant	Yes (X)	IndependentConsultantInd
Form990 Of Other Organizations	Yes (X)	Form990OfOtherOrganizationsInd
Written Employment Contract	Yes (X)	WrittenEmploymentContractInd
Compensation Survey	Yes (X)	CompensationSurveyInd
Board Or Committee Approval	Yes (X)	BoardOrCommitteeApprovalInd
Severance Payment	Yes (true)	SeverancePaymentInd
Supplemental Nonqual Rtr Plan	Yes (true)	SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm	false	EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org	false	CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs	false	CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org	false	CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs	false	CompBsdNetEarnsRltdOrgsInd
Any Non Fixed Payments	Yes (true)	AnyNonFixedPaymentsInd
Initial Contract Exception	false	InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (8 entries)

TitleTitleTxt	Base Compensation Filing OrgBaseCompensationFilingOrgAmt	Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt	Bonus Filing OrganizationBonusFilingOrganizationAmount	Bonus Related OrganizationsBonusRelatedOrganizationsAmt	Other Compensation Filing OrgOtherCompensationFilingOrgAmt	Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt	Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt	Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt	Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt	Total Compensation Filing OrgTotalCompensationFilingOrgAmt	Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt	Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt	Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
KRISTIINA VUORI MD PHD
PRESIDENT	$717,258	$0	$250,000	$0	$1,839	$0	$327,000	$0	$16,074	$0	$1,312,171	$0	$0	$0
GARY CHESSUM
CFO	$373,393	$0	$0	$0	$3,051	$0	$27,000	$0	$27,366	$0	$430,810	$0	$0	$0
GARTH POWIS PHD
CENTER DIRECTOR	$448,251	$0	$50,000	$0	$6,172	$0	$27,000	$0	$17,881	$0	$549,304	$0	$0	$0
DANIEL KELLY MD
CENTER DIR/SCI DIR AT LK NONA	$355,370	$0	$244,365	$0	$2,667	$0	$27,000	$0	$17,466	$0	$646,868	$0	$0	$0
EDWARD LEWANDOWSKI
PROFESSOR	$333,617	$0	$315,016	$0	$3,491	$0	$27,000	$0	$26,856	$0	$705,980	$0	$0	$0
CARL WARE PHD
CENTER DIRECTOR, IIDC	$369,875	$0	$18,351	$0	$5,123	$0	$27,000	$0	$17,954	$0	$438,303	$0	$0	$0
MICHAEL JACKSON PHD
DRUG DISCOVERY & DEV, SR VP	$385,546	$0	$0	$0	$3,051	$0	$27,000	$0	$27,059	$0	$442,656	$0	$0	$0
PERRY NISEN MD PHD
CEO (PART YEAR)	$687,208	$0	$250,000	$0	$268,438	$0	-$447,354	$0	$15,453	$0	$773,745	$0	$0	$0

Supplemental Information Detail SupplementalInformationDetail (5 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
FORM 990, SCHEDULE J, PART I, LINE 1A	FIRST CLASS TRAVEL FIRST CLASS TRAVEL IS GENERALLY NOT PERMITTED, EXCEPT UNDER VERY LIMITED AND RARE CIRCUMSTANCES AND CONDITIONS, SUCH AS A MEDICAL CONDITION REQUIREMENT AND URGENT CIRCUMSTANCES. THIS WAS NOT TREATED AS TAXABLE COMPENSATION. HEALTH OR SOCIAL CLUB DUES HEALTH OR SOCIAL CLUB DUES ARE NEGOTIATED IN THE HIRING PROCESS FOR CERTAIN EMPLOYEES. THE AMOUNTS WERE TREATED AS TAXABLE COMPENSATION.
FORM 990, SCHEDULE J, PART I, LINE 4A	DURING THE YEAR THE ORGANIZATION PAID SEVERANCE UNDER A CONFIDENTIAL SEVERANCE AGREEMENT TO ONE INDIVIDUAL.
FORM 990, SCHEDULE J, PART I, LINE 4B	SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN THE PARTICIPANTS OF THE 457(F) DEFERRED COMPENSATION PLAN ARE KRISTIINA VUORI AND PERRY NISEN. VESTING FOR KRISTIINA VUORI OCCURS THE EARLIEST OF 4/1/2020 & PERRY NISEN THE EARLIEST OF 9/15/19, OR INVOLUNTARY TERMINATION WITHOUT CAUSE, OR PARTICIPANT'S RESIGNATION FOR GOOD CAUSE, OR THE DATE OF TERMINATION OF THE PLAN. DISTRIBUTION IS A ONE-TIME LUMP SUM PAYMENT UPON VESTING OF 100% OF THE VALUE OF THE PARTICIPANT'S INVESTMENT (COMPRISED OF INSTITUTE CONTRIBUTIONS TO THE CORPUS PLUS ANY INVESTMENT GAINS OR LOSSES THEREON). AS DESCRIBED FURTHER BELOW, PERRY NISEN LEFT THE INSTITUTE WITHOUT VESTING, FORFEITING THE BALANCE ATTRIBUTED TO HIM.
FORM 990, SCHEDULE J, PART I, LINE 7	NON-FIXED PAYMENTS SOME SENIOR EXECUTIVES HAVE EMPLOYMENT AGREEMENTS STIPULATING A BONUS WILL BE PAID TO THEM PROVIDED CERTAIN GOALS OR ACCOMPLISHMENTS ARE ACHIEVED.
FORM 990, SCHEDULE J, PART II, COLUMN (C)	RETIREMENT AND OTHER DEFERRED COMPENSATION THE AMOUNT REPORTED IN SCHEDULE J, PART II, COLUMN C FOR KRISTIINA VUORI INCLUDES AN ACCRUAL OF $300,000 RELATED TO THE 457 (F) PLAN DESCRIBED ABOVE. PERRY NISEN INCLUDES THE FORFEITURE OF $447,354 DUE TO HIS RESIGNATION PRIOR TO VESTING IN THE 457 (F) PLAN. THESE AMOUNTS ARE NOT VESTED AND ARE SUBJECT TO SUBSTANTIAL RISK OF FORFEITURE.

Schedule K IRS990ScheduleK

Tax Exempt Bonds Issues TaxExemptBondsIssuesGrp

Field	Value	IRS element (for citing)
Bond Reference	A	BondReferenceCd

Issuer Name IssuerName

Field	Value	IRS element (for citing)
Business Name Line1	COUNTY OF SAN DIEGO	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Bond Issuer EIN	956000934	BondIssuerEIN
CUSIP	79742YAQ5	CUSIPNum
Bond Issued	2015-11-12	BondIssuedDt
Issue Price	$61,963,256	IssuePriceAmt
Purpose	SEE PART VI	PurposeDesc
Defeased	false	DefeasedInd
On Behalf Of Issuer	false	OnBehalfOfIssuerInd
Pool Financing	false	PoolFinancingInd

Tax Exempt Bonds Proceeds TaxExemptBondsProceedsGrp

Field	Value	IRS element (for citing)
Bond Reference	A	BondReferenceCd
Retired	$0	RetiredAmt
Bond Defeased	$61,673,870	BondDefeasedAmt
Total Proceeds	$61,963,256	TotalProceedsAmt
In Reserve Fund	$0	InReserveFundAmt
Capitalized Interest	$0	CapitalizedInterestAmt
Refunding Escrow	$0	RefundingEscrowAmt
Issuance Costs From Proceeds	$289,386	IssuanceCostsFromProceedsAmt
Credit Enhancement	$0	CreditEnhancementAmt
Working Capital Expenditures	$0	WorkingCapitalExpendituresAmt
Capital Expenditures	$0	CapitalExpendituresAmt
Other Spent Proceeds	$0	OtherSpentProceedsAmt
Unspent	$0	UnspentAmt
Substantial Completion	2015	SubstantialCompletionYr
Current Refunding	Yes (true)	CurrentRefundingInd
Advance Refunding	false	AdvanceRefundingInd
Final Allocation Made	Yes (true)	FinalAllocationMadeInd
Adequate Books And Rec Maint	Yes (true)	AdequateBooksAndRecMaintInd

Tax Exempt Bonds Private Bus Use TaxExemptBondsPrivateBusUseGrp

Field	Value	IRS element (for citing)
Bond Reference	A	BondReferenceCd
Owning Bond Financed Property	false	OwningBondFinancedPropertyInd
Any Lease Arrangements	Yes (true)	AnyLeaseArrangementsInd
Mgmt Contract Bond Fincd Prop	Yes (true)	MgmtContractBondFincdPropInd
Engage Bond Counsel Contracts	Yes (true)	EngageBondCounselContractsInd
Any Research Agreements	Yes (true)	AnyResearchAgreementsInd
Engage Bond Counsel Research	Yes (true)	EngageBondCounselResearchInd
Private Bus Use By Others	0.01530	PrivateBusUseByOthersPct
Total Private Business Use	0.01530	TotalPrivateBusinessUsePct
Bond Iss Meet Prvt Sec Pymt Test	false	BondIssMeetPrvtSecPymtTestInd
Change In Use Bond Financed Prop	false	ChangeInUseBondFinancedPropInd
Remedial Action Taken	false	RemedialActionTakenInd
Procs Nonqualified Bond Remdtd	Yes (true)	ProcsNonqualifiedBondRemdtdInd

Tax Exempt Bonds Arbitrage TaxExemptBondsArbitrageGrp

Field	Value	IRS element (for citing)
Bond Reference	A	BondReferenceCd
Form8038 T Filed	false	Form8038TFiledInd
Rebate Not Due Yet	Yes (true)	RebateNotDueYetInd
Exception To Rebate	false	ExceptionToRebateInd
No Rebate Due	false	NoRebateDueInd
Variable Rate Issue	Yes (true)	VariableRateIssueInd
Hedge Identified In Bks And Rec	false	HedgeIdentifiedInBksAndRecInd

Hedge Provider Name HedgeProviderName

Field	Value	IRS element (for citing)
Business Name Line1	0	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Gross Proceeds Invested In GIC	false	GrossProceedsInvestedInGICInd

GIC Provider Name GICProviderName

Field	Value	IRS element (for citing)
Business Name Line1	0	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Gross Proceeds Invested	false	GrossProceedsInvestedInd
Written Proc To Monitor Reqs	Yes (true)	WrittenProcToMonitorReqsInd

Procedures Corrective Action ProceduresCorrectiveActionGrp

Field	Value	IRS element (for citing)
Bond Reference	A	BondReferenceCd
Procedures Corrective Action	Yes (true)	ProceduresCorrectiveActionInd

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
SCHEDULE K, PART I, ROW A, COLUMN (F)	REFINANCE 2006 AND 2012 BONDS WITH ISSUE DATES OF 02/01/2006 AND 11/15/2012, RESPECTIVELY.
SCHEDULE K, PART I, ROW A	FOR THE BOND ISSUES LISTED IN PART I, THE ALTERNATIVE PERIOD USED FOR THE REPORTING REQUIREMENTS IN THIS SECTION IS THE TWELVE MONTHS ENDED DECEMBER 31, 2016.

Schedule L IRS990ScheduleL

Loans Btwn Org Interested Prsn LoansBtwnOrgInterestedPrsnGrp

Field	Value	IRS element (for citing)
Person	PERRY NISEN	PersonNm
Relationship With Org	OFFICER	RelationshipWithOrgTxt
Loan Purpose	QUAL. EMPLOYEE RELOC	LoanPurposeTxt
Loan From Organization	Yes (X)	LoanFromOrganizationInd
Original Principal	$1,000,000	OriginalPrincipalAmt
Balance Due	$911,111	BalanceDueAmt
Default	false	DefaultInd
Board Or Committee Approval	Yes (true)	BoardOrCommitteeApprovalInd
Written Agreement	Yes (true)	WrittenAgreementInd

Field	Value	IRS element (for citing)
Total Balance Due	$911,111	TotalBalanceDueAmt

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (9 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
FORM 990, PART I, LINE 1 & PART III, LINE 1	ORGANIZATIONS MISSION SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE CONDUCTS WORLD-CLASS, COLLABORATIVE RESEARCH DEDICATED TO FINDING CURES FOR HUMAN DISEASE, IMPROVING THE QUALITY OF LIFE, AND THUS CREATING A LEGACY FOR ITS EMPLOYEES, PARTNERS, DONORS, AND COMMUNITY.
FORM 990, PART III, LINE 4	PROGRAM SERVICE ACCOMPLISHMENTS SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (SBP) IS AN INDEPENDENT NONPROFIT MEDICAL RESEARCH ORGANIZATION THAT CONDUCTS WORLD-CLASS, COLLABORATIVE, BIOLOGICAL RESEARCH AND TRANSLATES ITS DISCOVERIES FOR THE BENEFIT OF PATIENTS. SBP FOCUSES ITS RESEARCH ON CANCER, IMMUNITY, NEURODEGENERATION, METABOLIC DISORDERS AND RARE CHILDREN'S DISEASES. CANCER ANTI-CANCER DRUG SHORT-CIRCUITS CANCER SIGNALING. XAIO-KUN ZHANG, PH.D., PUBLISHED A STUDY IN NATURE COMMUNICATIONS THAT SHEDS NEW LIGHT ON HOW K-80003 (TX803), AN ANTI-CANCER AGENT DISCOVERED AT SBP, INHIBITS CANCER CELL GROWTH. THE COMPOUND IS IN A CLINICAL TRIAL FOR COLON CANCER AT THE DANA FARBER CANCER CENTER. IMMUNE SCAVENGER CELLS: GOOD GUYS OR BAD GUYS? WILLIAM STALLCUP, PH.D., PUBLISHED A STUDY IN TRENDS IN CELL AND MOLECULAR BIOLOGY DESCRIBING ONE WAY THAT CANCER CELLS TRANSFORM MACROPHAGES FROM TUMOR FIGHTERS INTO TUMOR HELPERS. LOCATION MATTERS, EVEN FOR TUMORS. LOCATION, LOCATION, LOCATION! WE OFTEN HEAR THIS IN REAL ESTATE, BUT ITS ALSO TRUE IN BIOLOGY. WILLIAM STALLCUP, PH.D., PUBLISHED A PAPER IN CANCERS DESCRIBING THE IMPORTANCE OF LOCATION FOR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), A PROTEIN THAT RECRUITS NEW BLOOD VESSELS TO "FEED" TUMORS WITH OXYGEN AND NUTRIENTS. NOVEL "DOT" SYSTEM IMPROVES CANCER IMAGING. TUMOR IMAGING IS A KEY COMPONENT OF CANCER CARE. DETECTION, TREATMENT AND TRACKING PATIENT PROGRESS ALL RELY ON METHODS USED TO VISUALIZE TUMORS. ERKKI RUOSLAHTI, M.D., PH.D., AND COLLEAGUES HAVE DEVELOPED A NEW SYSTEM USING QUANTUM DOTS THAT ACHIEVES A FIVE-FOLD IMPROVEMENT OVER EXISTING TUMOR-SPECIFIC OPTICAL IMAGING METHODS. THE STUDY WAS PUBLISHED IN NATURE COMMUNICATIONS. NEW INSIGHTS ON THE ADDICTIONS OF TUMORS. MARIA DIAZ-MECO, PH.D., PUBLISHED RESEARCH SUGGESTING THAT TARGETING THE P62 PROTEIN IN THE SUPPORTIVE TISSUE SURROUNDING TUMORS MAY CUT OFF THE SUPPLY OF NUTRIENTS THAT FEED THE GROWTH AND SURVIVAL OF MANY CANCERS. THE FINDINGS SUGGEST THAT THIS PROTEIN COULD BE A POTENTIAL ANTI-CANCER TARGET. THE STUDY WAS PUBLISHED IN CELL METABOLISM. STOPPING PANCREATIC CANCER BEFORE IT STARTS. A STUDY CO-AUTHORED BY JORGE MOSCAT, PH.D., AND MARIA DIAZ-MECO, PH.D., LOOKS AT WAYS TO DETECT AND STOP PRECURSORS OF PANCREATIC CANCER-CALLED PANIN1 LESIONS-BEFORE THEY BECOME CANCER. THE FINDINGS SUGGEST SMALL MOLECULES THAT INHIBIT A PROTEIN CALLED MDM2, WHICH IS INVOLVED IN PANCREATIC CANCER PROGRESSION, MAY BE EFFECTIVE AT PREVENTING PANIN1 LESIONS FROM TURNING MALIGNANT. THE STUDY WAS PUBLISHED IN CANCER CELL. HOW SHARPIN PROMOTES CANCER PROGRESSION. ZEEV RONAI, PH.D., LED AN INTERNATIONAL RESEARCH COLLABORATION SHOWING HOW THE SHARPIN PROTEIN ACTS AS A MASTER SWITCH THAT CONTROLS SEVERAL OTHER PROTEINS LINKED TO MELANOMA. INHIBITING SHARPIN MAKES CERTAIN TYPES OF TUMOR CELLS MORE SUSCEPTIBLE TO DEATH AND COULD BOOST THE OVERALL EFFECTIVENESS OF CERTAIN ANTI-CANCER THERAPIES. THE RESEARCH WAS PUBLISHED IN THE JOURNAL OF CLINICAL INVESTIGATION. HOW FAT TISSUE SHUNTS ENERGY TO TUMORS. OBESITY IS KNOWN TO BE A MAJOR RISK FACTOR FOR PROSTATE CANCER AND PREDICTS HOW AGGRESSIVELY THE CANCER WILL BEHAVE. BUT IT HAS NOT BEEN CLEAR HOW OBESITY CONTRIBUTES TO TUMOR FORMATION. A STUDY BY MARIA DIAZ-MECO, PH.D., AND JORGE MOSCAT, PH.D., PUBLISHED IN CANCER CELL, LOOKS AT HOW CANCER DERIVES FUEL FROM FAT CELLS AND DESCRIBES A POTENTIAL APPROACH TO STARVE TUMORS OF NUTRITION. ADVANCING EFFORTS TO STARVE CANCER TO DEATH. FOR YEARS, SCIENTISTS HAVE TRIED TO HALT CANCER BY BLOCKING THE NUTRIENTS THAT CANCER CELLS NEED TO GROW AND PROLIFERATE. THESE STRATEGIES HAVE OFTEN FAILED BECAUSE CANCER CELLS ARE CRAFTY-THEY HAVE BACKUP PLANS TO GATHER THE FOOD AND OXYGEN THAT THEY NEED TO SURVIVE. BROOKE EMERLING, PH.D., LED RESEARCH REVEALING AN ALTERNATIVE METABOLIC PATHWAY USED BY CANCER CELLS THAT MAY BE TARGETED TO STARVE TUMORS. THE STUDY WAS PUBLISHED IN MOLECULAR CELL. COMPARING ALGORITHMS THAT SEARCH FOR CANCER MUTATIONS. A TEAM OF INTERNATIONAL SCIENTISTS LED BY ADAM GODZIK, PH.D., HAS UNDERTAKEN THE FIRST-EVER COMPARATIVE ANALYSIS OF A NEWLY EMERGING CATEGORY OF ALGORITHMS THAT MINE CANCER DATABASES BY FOCUSING ON INTERNAL GENE STRUCTURE (SUBGENE RESOLUTION ALGORITHMS). THE STUDY WAS PUBLISHED IN NATURE METHODS AND REVIEWED, CLASSIFIED AND DESCRIBED THE STRENGTHS AND WEAKNESSES OF MORE THAN 20 ALGORITHMS DEVELOPED BY INDEPENDENT RESEARCH GROUPS. HOW RNA SPLICING CAN TRIGGER CANCER. UNTIL RECENTLY, ONLY DNA MUTATIONS WERE THOUGHT TO CAUSE CANCER. ADAM GODZIK, PH.D., HAS PUBLISHED RESEARCH IN CELL REPORTS SHOWING HOW ALTERATIONS IN A PROCESS KNOWN AS ALTERNATIVE RNA SPLICING MAY ALSO TRIGGER THE DISEASE. DISORDERS OF METABOLISM "TOXIC FAT" DIRECTLY LINKED TO HEART DYSFUNCTION. A STUDY BY ROLF BODMER, PH.D., IS THE FIRST TO PROVIDE DIRECT EVIDENCE LINKING THE ACCUMULATION OF A TYPE OF LIPID (FAT) CALLED CERAMIDES TO LIPOTOXIC CARDIOMYOPATHY-A HEART CONDITION THAT OFTEN OCCURS IN PATIENTS WITH DIABETES AND OBESITY. THE RESEARCH SUGGESTS THAT CERAMIDE LEVELS NEED TO STAY WITHIN A WELL-BALANCED RANGE TO ENSURE ROBUST HEART FUNCTION AND IDENTIFIES SEVERAL NEW POTENTIAL THERAPEUTIC TARGETS THAT COULD PREVENT OR REVERSE THE EFFECTS OF THE CONDITION. THE FINDINGS WERE PUBLISHED IN CELL REPORTS. HOW CAN PREBIOTICS HELP YOUR GUT HEALTH? WORDS LIKE MICROBIOME, GUT HEALTH, AND PROBIOTICS ARE NOW PART OF OUR COMMON VOCABULARY. BUT LITTLE HAS BEEN MENTIONED ABOUT "PREBIOTICS". SCOTT PETERSON, PH.D., WORKED WITH UC SAN DIEGO AND THE CHOPRA FOUNDATION TO ASSESS THE PREBIOTIC EFFECTS OF HERBS COMMONLY USED IN AYURVEDIC MEDICINE-A SYSTEM PRACTICED IN INDIA FOR MORE THAN 5,000 YEARS. THE STUDY WAS PUBLISHED IN THE JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE. A NEW APPROACH TO RESTORE INSULIN PRODUCTION IN DIABETES. IF YOU ARE A DIABETIC, THERE IS A STRONG CHANCE YOU ARE EITHER ON INSULIN THERAPY NOW OR WILL BE IN THE FUTURE. THIS HOLDS TRUE FOR TYPE 1 AND TYPE 2 DIABETICS; BOTH TYPES LEAD TO ELEVATED BLOOD GLUCOSE LEVELS. FRED LEVINE, M.D., PH.D., HAS ADVANCED EFFORTS TO REGENERATE PANCREATIC BETA CELLS-THE CELLS THAT STORE AND SECRETE INSULIN. THIS RESEARCH, PUBLISHED IN ISLETS, COULD ONE DAY FREE MILLIONS OF PATIENTS FROM DAILY DOSES OF INSULIN.
IMMUNITY	VIRAL TRICKS INSPIRE AUTOIMMUNE DRUG DESIGN. VIRUSES HAVE WAYS TO TURN OFF THE HOST IMMUNE SYSTEM TO AVOID BEING ATTACKED. CARL WARE, PH.D., IS LEADING EFFORTS TO MAKE A NEW DRUG TO TREAT AUTOIMMUNE DISORDERS USING THE SAME STRATEGIES THAT HERPES VIRUSES USE TO DAMPEN THE IMMUNE RESPONSE. THE FINDINGS WERE PUBLISHED IN THE JOURNAL OF BIOLOGICAL CHEMISTRY. MILD FOOD POISONING MAY NOT BE SO HARMLESS. FOOD POISONING MAY BE THE UNWANTED GIFT THAT KEEPS ON GIVING-AT LEAST ACCORDING TO A STUDY BY JAMEY MARTH, PH.D. A PAST HISTORY OF BACTERIAL INFECTIONS, SUCH AS SALMONELLA FOOD POISONING, CAN ULTIMATELY LEAD TO CHRONIC INFLAMMATION AND LIFE-THREATENING COLITIS. THE RESEARCH, PUBLISHED IN SCIENCE, MAY ALSO IDENTIFY THE LONG-MYSTERIOUS CAUSE OF INFLAMMATORY BOWEL DISEASE. NEW INSIGHTS INTO T CELL SURVIVAL. A HEALTHY POOL OF CIRCULATING T CELLS IS ESSENTIAL TO KILL PATHOGENS, MAKE ANTIBODIES, SHUT DOWN THE IMMUNE SYSTEM TO PREVENT UNCONTROLLED INFLAMMATION AND AUTOIMMUNE DISORDERS-AND EVEN FIGHT CANCER. A STUDY BY MAXIMILIANO DANGELO, PH.D., IDENTIFIED A NUCLEAR PORE PROTEIN THAT IS CRITICAL FOR THE SURVIVAL OF CIRCULATING T CELLS, PAVING THE WAY FOR POTENTIAL ADVANCES IN IMMUNOTHERAPY. THE FINDINGS WERE PUBLISHED IN NATURE IMMUNOLOGY. HARNESSING NANOPARTICLES TO FIGHT DRUG-RESISTANT INFECTIONS. THE RACE AGAINST TIME TO DEVELOP NEW ANTIBIOTICS IS MORE IMPORTANT THAN EVER. ERKKI RUOSLAHTI, M.D., PH.D., CO-AUTHORED A STUDY PUBLISHED IN NATURE COMMUNICATIONS THAT DESCRIBES THE FIRST EXAMPLE OF AN EFFECTIVE GENE THERAPEUTIC APPROACH TO FIGHT LETHAL BACTERIAL INFECTIONS. WILL AN ANTI-MALARIA DRUG WORK FOR ZIKA VIRUS? ALTHOUGH THE ZIKA VIRUS MAY SEEM LIKE LAST YEARS HEALTH CRISIS, IT REMAINS A GLOBAL RISK THAT CAN CAUSE SEVERE FETAL BRAIN DEFECTS. FINDINGS FROM A STUDY LED BY ALEXEY TERSKIKH, PH.D. SUGGEST THAT THE ANTI-MALARIA DRUG CHLOROQUINE MAY BE A SAFE AND EFFECTIVE DRUG TO PREVENT AND TREAT ZIKA INFECTION. THE RESEARCH WAS PUBLISHED IN SCIENTIFIC REPORTS. OFF-THE-SHELF DRUGS COULD HELP MANAGE ZIKA. THE ZIKA VIRUS HAS BEEN RELATIVELY QUIET LATELY, BUT THAT DOESN'T MEAN THE DANGER IS OVER. ZIKA CAN COME BACK AT ANY TIME, CAUSING BIRTH DEFECTS AND OTHER HEALTH ISSUES. ALEXEY TERSKIKH, PH.D., CO-AUTHORED A STUDY SHOWING THAT SOFOSBUVIR, AN ANTIVIRAL DRUG CURRENTLY USED TO TREAT HEPATITIS C, COULD ALSO BE EFFECTIVE AGAINST ZIKA. PLANS ARE UNDERWAY TO TEST SOFOSBUVIR AS PART OF A DRUG COCKTAIL-A COMBINATION OF THREE OR FOUR DRUGS-TO POTENTIALLY HELP STEM FUTURE OUTBREAKS. THE FINDINGS WERE PUBLISHED IN NATURE SCIENTIFIC REPORTS. NOVEL GENOME PLATFORM WILL HELP TARGET "UNDRUGGABLE" DISEASE-CAUSING PROTEINS. A NEW TECHNOLOGY TERMED GLOBAL ARRAYED PROTEIN STABILITY ANALYSIS (GASPA) MAY HELP RESEARCHERS SCREEN FOR AND DEVELOP DRUGS THAT ELIMINATE DISEASE-CAUSING PROTEINS THAT ARE CURRENTLY DEEMED "UNDRUGGABLE." THE STUDY WAS LED BY SUMIT CHANDA, PH.D. GASPA MAY DRAMATICALLY EXPAND DRUG DEVELOPMENT IN THE MOST DIFFICULT-TO-TREAT DISEASES, SUCH AS ALZHEIMERS DISEASE, CANCER, AUTOIMMUNE DISORDERS, INFECTIOUS DISEASES AND MORE. THE STUDY WAS PUBLISHED IN CELL REPORTS. NEUROSCIENCE BIOMARKER MAY PREDICT EARLY ALZHEIMERS DISEASE. ERKKI RUOSLAHTI, M.D., PH.D., DISCOVERED A NOVEL APPROACH FOR DETECTING ALZHEIMERS DISEASE AT ITS EARLIEST STAGES. HIS RESEARCH TEAM FOUND A BIOLOGICAL MARKER, OR BIOMARKER, THATS ASSOCIATED WITH BRAIN INFLAMMATION-A PRECURSOR TO THE FORMATION OF HALLMARK AMYLOID PLAQUES AND THE DEVELOPMENT OF ALZHEIMERS DISEASE SYMPTOMS. THE FINDINGS WERE PUBLISHED IN NATURE COMMUNICATIONS. HOW SORLA PROTECTS AGAINST ALZHEIMERS DISEASE. HUAXI XU, PH.D., IDENTIFIED A PROTECTIVE FUNCTION FOR A BRAIN PROTEIN GENETICALLY LINKED TO ALZHEIMERS DISEASE. THE PROTEIN, CALLED SORLA, LIMITS THE ABILITY OF AMYLOID BETA, THE TOXIC PROTEIN THAT CAUSES ALZHEIMERS, TO TRIGGER THE DESTRUCTION OF NEURONS. THE FINDINGS WERE PUBLISHED IN THE JOURNAL OF EXPERIMENTAL MEDICINE. MAPPING THE ORIGINS OF ALZHEIMERS, PARKINSONS, SCHIZOPHRENIA AND OTHER BRAIN DISORDERS. BY ANALYZING BRAIN CELLS ONE AT A TIME, RESEARCHERS ARE ABLE TO NARROW DOWN AND RANK THE CELL TYPES THAT CARRY THE MOST GENETIC RISK FOR DEVELOPING BRAIN DISORDERS. JEROLD CHUN, M.D., PH.D., CO-AUTHORED A STUDY ADVANCING THE TECHNOLOGY USED TO MAP THE CELL ORIGINS OF VARIOUS BRAIN DISORDERS, INCLUDING ALZHEIMERS, PARKINSONS, SCHIZOPHRENIA AND BIPOLAR DISORDER. THE STUDY WAS PUBLISHED IN NATURE BIOTECHNOLOGY. DISCOVERY MAY ADVANCE STEM CELL TREATMENTS FOR BRAIN DISORDERS. BEING ABLE TO MAINTAIN VIABLE STEM CELLS IN THE BRAIN COULD LEAD TO REGENERATIVE THERAPIES TO TREAT ALZHEIMER'S DISEASE, PARKINSON'S DISEASE AND MENTAL HEALTH DISORDERS THAT AFFECT COGNITIVE ABILITIES. JING CRYSTAL ZHAO, PH.D., PUBLISHED A STUDY IN NATURE NEUROSCIENCE REVEALING A PREVIOUSLY UNKNOWN BUT ESSENTIAL STEP IN REGULATING NEURAL STEM SELF-RENEWAL. THE RESEARCH ALSO OPENS NEW POSSIBILITIES FOR CORRECTING ABNORMAL GENE ACTIVITY IN BRAIN DISORDERS WITH PRECISION. THE BRAINS IMMUNE SYSTEM MAY BE KEY TO NEW ALZHEIMERS TREATMENTS. TWO STUDIES PUBLISHED IN NEURON BY HUAXI XU, PH.D., DESCRIBE HOW TREM2, A RECEPTOR FOUND ON IMMUNE CELLS IN THE BRAIN, INTERACTS WITH TOXIC AMYLOID BETA PROTEINS TO RESTORE NEUROLOGICAL FUNCTION. THE RESEARCH, PERFORMED ON MOUSE MODELS OF ALZHEIMERS DISEASE, SUGGESTS BOOSTING TREM2 LEVELS IN THE BRAIN MAY PREVENT OR REDUCE THE SEVERITY OF NEURODEGENERATIVE DISORDERS INCLUDING ALZHEIMERS DISEASE. CHILDRENS HEALTH RESEARCH TAKES STEPS TOWARDS A PROMISING THERAPY FOR A RARE BONE DISEASE. YU YAMAGUCHI, M.D., PH.D., LED RESEARCH THAT MAY PRODUCE THE FIRST DRUG TO TREAT PATIENTS WITH MULTIPLE HEREDITARY EXOSTOSES (MHE), A GENETIC DISORDER THAT CAUSES THE GROWTH OF MULTIPLE BENIGN BONE TUMORS. PATIENTS WITH THE PAINFUL, OFTEN DEBILITATING DISEASE ARE CURRENTLY LIMITED TO SURGERY, PHYSICAL THERAPY AND PAIN MANAGEMENT AS TREATMENTS. THE RESEARCH WAS PUBLISHED IN JCI INSIGHT. UNCOVERING THE CAUSE OF A 12-YEAR-OLD GIRLS RARE NEUROLOGICAL DISORDER. THE PARENTS OF A CHILD WITH SEIZURES, WEAK MUSCLES, LIMITED COMMUNICATION ABILITIES AND AUTISM-LIKE BEHAVIOR RECENTLY GOT A LONG-AWAITED ANSWER AS TO THE CAUSE OF HER DISORDER. HUDSON FREEZE, PH.D., HELPED IDENTIFY THE SOURCE OF HER SYMPTOMS, WHICH TURNED OUT TO STEM FROM IMPROPER FUNCTION OF A PROTEIN IMPORTANT FOR BRAIN DEVELOPMENT. THE STUDY WAS PUBLISHED IN THE AMERICAN JOURNAL OF MEDICAL GENETICS. NEW CLUES TO TREAT ALAGILLE SYNDROME. DUC DONG, PH.D., SHED NEW LIGHT ON HOW LIVER DUCTS ARE FORMED. THE RESEARCH, PERFORMED IN ZEBRAFISH, IS ESPECIALLY MEANINGFUL FOR PATIENTS WITH ALAGILLE SYNDROME, WHO HAVE FEWER THAN THE NORMAL NUMBER OF LIVER DUCTS, CAUSING JAUNDICE, LIVER DISEASE AND LIVER FAILURE. THE FINDINGS WERE PUBLISHED IN NATURE COMMUNICATIONS. PRECLINICAL STUDY DEMONSTRATES PROMISING TREATMENT FOR RARE BONE DISEASE. YU YAMAGUCHI, M.D., PH.D., LED A STUDY SHOWING THAT THE DRUG PALOVAROTENE SUPPRESSES THE FORMATION OF BONY TUMORS IN MODELS OF MULTIPLE HEREDITARY EXOSTOSES. THE RESEARCH IS A PROMISING STEP TOWARD AN EFFECTIVE TREATMENT FOR THE RARE GENETIC CONDITION THAT MOSTLY AFFECTS CHILDREN. THE RESEARCH WAS PUBLISHED IN THE JOURNAL OF BONE AND MINERAL RESEARCH. DIAGNOSING A RARE DISEASE IN CHILDREN. CHILDREN BORN WITH RARE INHERITED CONDITIONS KNOWN AS CONGENITAL DISORDERS OF GLYCOSYLATION, OR CDG, OFTEN LIVE FOR YEARS BEFORE THEY RECEIVE A DIAGNOSIS. THESE DISEASES CAN CAUSE SERIOUS, SOMETIMES FATAL, MALFUNCTIONS OF THE NERVOUS SYSTEM, MUSCLES AND INTESTINES. HUDSON FREEZE, PH.D., LED AN INTERNATIONAL TEAM OF SCIENTISTS AND CLINICIANS WHO DIAGNOSED THREE CHILDREN WITH A PREVIOUSLY UNDIAGNOSED FORM OF CDG AND LINKED THEIR DISEASE TO SPECIFIC GENETIC MUTATIONS. IN ADDITION TO BROADENING OUR UNDERSTANDING OF CGD, THE STUDY ALSO POINTS TO A DIAGNOSTIC TEST THAT COULD BE USED FOR EARLY DETECTION FOR THIS AND OTHER RARE GENETIC DISORDERS. THE STUDY WAS PUBLISHED IN THE AMERICAN JOURNAL OF HUMAN GENETICS.
AGING	SCIENTISTS TAKE A DEEPER DIVE INTO CELLULAR TRASH. MALENE HANSEN, PH.D., LED THE FIRST-EVER COMPREHENSIVE ANALYSIS OF AUTOPHAGY IN A LIVING ANIMAL DURING AGING. THE STUDY WAS PUBLISHED IN ELIFE. WILL FLIES HELP FIX HEART RHYTHM PROBLEMS? KAREN OCORR, PH.D., PUBLISHED A STUDY IN PLOS GENETICS DESCRIBING HOW DROSOPHILA HEARTS MAY BECOME AN EASY, ACCURATE TOOL TO SCREEN FOR NEW DRUGS TO TREAT ARRHYTHMIAS. WHERE DO HEART CELLS COME FROM? A STUDY BY ALEX COLAS, PH.D., IDENTIFIED FOUR GENES THAT PLAY A CRUCIAL ROLE IN HEART DEVELOPMENT. THE GENES, CALLED "ID" GENES, DIRECT STEM CELLS TO BECOME HEART CELLS. THE RESEARCH WILL ENABLE SCIENTISTS TO GENERATE UNLIMITED AMOUNTS OF CELLS FOR CARDIAC DISEASE MODELING AND DRUG DISCOVERY. THE STUDY WAS PUBLISHED IN THE JOURNAL GENES & DEVELOPMENT. THE SLOW, SILENT PROCESS OF "INFLAMMAGING" MIGHT KILL YOU. IN AGING CELLS THAT STOP GROWING AND DIVIDING, BITS OF DNA NORMALLY CONFINED TO THE CELL NUCLEUS LEAK OUT INTO THE CYTOPLASM. PETER ADAMS, PH.D., PUBLISHED A STUDY ON HOW THIS CAN LEAD TO CHRONIC INFLAMMATION AND AGE-RELATED DISEASES SUCH AS RHEUMATOID ARTHRITIS, LIVER DISEASE, ATHEROSCLEROSIS, MUSCLE WASTING AND CANCER. THE RESEARCH WAS PUBLISHED IN NATURE. NEW AVENUE TO PURSUE TREATMENT FOR SECONDARY HYPERTENSION. ABOUT 10 PERCENT OF PEOPLE WITH HIGH BLOOD PRESSURE HAVE SECONDARY HYPERTENSION, A CONDITION MOST COMMONLY CAUSED BY HYPERALDOSTERONISM, IN WHICH THE ADRENAL GLANDS PRODUCE TOO MUCH OF THE HORMONE ALDOSTERONE. ZEEV RONAI, PH.D., LED A STUDY THAT PROVIDES INSIGHTS INTO THE DEVELOPMENT OF ADRENAL GLANDS AND THE PRODUCTION OF ALDOSTERONE, POINTING TO POSSIBLE THERAPEUTIC TARGETS FOR HYPERALDOSTERONISM. THE FINDINGS WERE PUBLISHED IN JCI INSIGHT. HOW YOUR MUSCLE STEM CELLS COPE WITH INJURY AND AGING. ADULT MUSCLE STEM CELLS ARE ESSENTIAL FOR REPAIRING AND REGENERATING MUSCLE THROUGHOUT LIFE. RESEARCH FROM ALESSANDRA SACCO, PH.D., DESCRIBED THE BIOLOGICAL DIFFERENCES BEHIND HOW MUSCLE STEM CELLS RESPOND TO AGING COMPARED TO A SUDDEN INJURY. THE FINDINGS, PUBLISHED IN CELL STEM CELL, HAVE IMPLICATIONS FOR FUTURE THERAPIES TO HELP SENIORS MAINTAIN MUSCLE MASS AND STRENGTH AND FOR PATIENTS WITH MUSCLE DISEASES SUCH AS MUSCULAR DYSTROPHY. A KEY TO REGENERATING BLOOD VESSELS. MASANOBU KOMATSU, PH.D., PUBLISHED RESEARCH THAT SHEDS LIGHT ON THE DISTINCT STEPS AND SIGNALS NEEDED TO CREATE NEW BLOOD VESSELS FROM PRE-EXISTING VESSELS. THE STUDY OPENS A RESEARCH APPROACH TO IMPROVING BLOOD FLOW IN ISCHEMIC TISSUE, SUCH AS THAT FOUND IN ATHEROSCLEROSIS AND PERIPHERAL VASCULAR DISEASE ASSOCIATED WITH DIABETES. THE FINDINGS WERE PUBLISHED IN NATURE COMMUNICATIONS. FIXING "LEAKY" BLOOD VESSELS TO HALT CANCER. SOMETIMES BLOOD VESSELS CAN BECOME LEAKY, A CONDITION KNOWN AS VASCULAR PERMEABILITY. THIS CAN BE A BIG PROBLEM, PARTICULARLY IN CANCER, ALLOWING TUMOR CELLS TO GET INTO THE BLOODSTREAM AND TRAVEL THROUGHOUT THE BODY. RESEARCHERS IN THE LAB OF MASANOBU KOMATSU, PH.D., MADE RESEARCH ADVANCES TOWARD KEEPING BLOOD VESSELS FROM LEAKING AND LIMIT CANCER FROM SPREADING. THE STUDY WAS PUBLISHED IN THE FASEB JOURNAL. TRANSLATIONAL MEDICINE A MILESTONE FOR LOCAL ALZHEIMER'S DISEASE DRUG DISCOVERY RESEARCH. THE COLLABORATION4CURE (C4C) INITIATIVE REALIZED A RETURN ON INVESTMENT WHEN AN SBP RESEARCH PROJECT WAS RECENTLY AWARDED A THREE-YEAR $1.3M R01 NIH GRANT. C4C FUNDS AND A GENEROUS DONATION FROM STUART AND KAREN TANZ CONTRIBUTED TO THE DEVELOPMENT OF ROBUST PRELIMINARY DATA TO SUPPORT THE COMPETITIVE GRANT APPLICATION. PARTNERING WITH TAKEDA. A SERVICE AGREEMENT WITH TAKEDAS R&D SITE IN SAN DIEGO HAS QUICKLY ESTABLISHED THE PREBYS CENTER AS A PROVIDER-OF-CHOICE FOR SCREENING PROJECTS. BY THE CLOSE OF FY18, THE CENTER WILL COMPLETE FIVE TAKEDA PROJECTS AND GENERATE ~$1M IN REVENUE. AGREEMENT WITH SANOFI A MATERIAL TRANSFER AGREEMENT WAS EXECUTED WITH SANOFI FOR THE LMPTP-A COLLABORATIVE PROJECT BETWEEN THE PREBYS CENTER AND NUNZIO BOTTINI, PH.D. AT UCSD. THE RESEARCH INVOLVES A SERIES OF ALLOSTERIC MODULATOR WITH POTENTIAL CARDIOVASCULAR AND METABOLIC DISEASE INDICATIONS. PROGRESS IN SUBSTANCE ABUSE DRUG DISCOVERY. AN INITIAL CLINICAL DRUG CANDIDATE HAS BEEN SELECTED BY NICHOLAS COSFORD, PH.D., AND A RESEARCH TEAM THAT SEEKS TO DEVELOP A DRUG FOR THE TREATMENT OF SUBSTANCE ABUSE. THE PROJECT, FUNDED BY A $10.8M U01 GRANT FROM THE NATIONAL INSTITUTE ON DRUG ABUSE (NIDA), WAS INITIATED ON SEPTEMBER 1, 2017. THE ULTIMATE GOAL OF THE PROJECT IS TO DELIVER A CLINICAL CANDIDATE TO TREAT DEPENDENCE ON NICOTINE AND OTHER ADDICTIVE SUBSTANCES BY Q2, 2020. COLLABORATIVE CANCER RESEARCH ON THE TORREY PINES MESA. PROCEEDS FROM THE NOVEMBER 2017 PADRES PEDAL THE CAUSE (PTC) CYCLING EVENT WILL BE AWARDED IN JUNE 2018 TO SAN DIEGO NCI CANCER CENTERS AND PEER RESEARCH ORGANIZATIONS TO STIMULATE COLLABORATION AND INNOVATIVE TRANSLATIONAL CANCER RESEARCH. SBP CANCER RESEARCHERS SUBMITTED 10 APPLICATIONS. LAST YEAR, SBP RESEARCHERS RECEIVED $304,798 FROM PTC GRANTS. CLINICAL PARTNERSHIPS. ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (ISMMS) AND SBP SIGNED A MEMORANDUM OF UNDERSTANDING TO ENTER INTO A DRUG DISCOVERY COLLABORATION TO LEVERAGE ISMMS BASIC AND CLINICAL RESEARCH CAPABILITIES WITH TRANSLATIONAL RESEARCH EXPERTISE AT SBP TO DRIVE SCIENTIFIC DISCOVERIES TO THE CLINIC. IN ADDITION, THE WANEK FOUNDATION AT MAYO CLINIC IN ROCHESTER (MN) AND THE BODMER, OCORR AND COLAS LABS ESTABLISHED A MULTI-MILLION-DOLLAR PARTNERSHIP TO EXAMINE CONGENITAL HEART DISEASE GENE CANDIDATES. THE STUDY WILL INCLUDE WHOLE GENOME SEQUENCING OF 120 PATIENTS WITH HYPOPLASTIC LEFT HEART SYNDROME, WITH THE AIM OF ELUCIDATING THE GENETIC CAUSES UNDERLYING THIS DISEASE. ELUCIDATION OF NOVEL PANDEMIC INFLUENZA THERAPEUTICS. IN AN AGREEMENT WITH CIDARA THERAPEUTICS EXECUTED IN JANUARY 2017, THE CHANDA LAB WILL COMMENCE IN VITRO VALIDATION STUDIES THIS QUARTER TO INVESTIGATE THE ANTIVIRAL PROPERTIES OF THREE SMALL MOLECULES DESIGNED AND PROVIDED BY CIDARA TO TARGET INFLUENZA VIRUS. THIS WORK COULD LEAD TO THE DEVELOPMENT OF NOVEL ANTIVIRAL DRUGS TO PREVENT, MITIGATE AND TREAT INFECTIONS BY INFLUENZA TYPE A AND B VIRUSES. ENGINEERING DRUGS TURNING ON IMMUNE CHECKPOINTS. JOHN SEDY, PH.D., AND CARL WARE, PH.D., SUCCESSFULLY DEVELOPED A PROTOTYPE BIOLOGIC THAT CAN TONE DOWN THE IMMUNE SYSTEM FOR POTENTIAL USE IN PATIENTS WITH AUTOIMMUNE DISEASES. THE DRUG IS CREATED FROM THE CHICK-POINT REGULATOR KNOW AS HERPESVIRUS ENTRY MEDIATOR (HVEM). NCI CHEMICAL BIOLOGY CONSORTIUM AWARDS TWO CANCER THERAPEUTICS PROJECTS. THE NATIONAL CANCER INSTITUTES CHEMICAL BIOLOGY CONSORTIUM (CBC) SEEKS TO ADVANCE CLINICAL PRACTICE AND BRING IMPROVED THERAPIES TO PATIENTS WITH CANCER BY SUPPORTING THE MOST PROMISING NEW DRUG DISCOVERY AND DEVELOPMENT PROJECTS. THE CONSORTIUM HAS BEEN TASKED TO WORK ON BOTH OF THESE PROJECTS FROM FACULTY LABS AT SBP. THE PREBYS CENTER WORKS ON BOTH OF THESE PROJECTS WITH THE GOAL OF IDENTIFYING AND VALIDATING CHEMICAL HITS PRIOR TO MOVING INTO MORE ADVANCED STAGES OF DRUG DISCOVERY. - LUTZ TAUTZ, PH.D., AND NICK COSFORD, PH.D., RECEIVED AN AWARD FOR DRUG DISCOVERY EFFORTS LOOKING TO INHIBIT SHP2, A TARGET IMPLICATED IN A NUMBER OF CANCERS, MOST NOTABLY LEUKEMIAS, AND HER2-POSITIVE AND TRIPLE-NEGATIVE BREAST CANCERS. - JORGE MOSCAT, PH.D., AND MARIA DIAZ-MECO, PH.D., HAVE A PROJECT THAT TARGETS PHGDH, A PROTEIN INVOLVED IN CANCER METABOLISM, THAT WAS SELECTED TO ENTER THE CBC PORTFOLIO, ATTRACTING AN AWARD OF $1.65M FOR THE INITIAL PHASES OF DRUG DISCOVERY, WHICH INCLUDED BOTH HIGH THROUGHPUT SCREENING, MEDICINAL CHEMISTRY AND STRUCTURE-BASED DESIGN. COLORECTAL CANCER. THE COMPOUND TX803, IDENTIFIED BY THE RESEARCH OF XIAO-KUN ZHANG, PH.D., ENTERED A PHASE 1 CLINICAL TRIAL FOR ADVANCED COLORECTAL CANCER IN PARTNERSHIP WITH TARREX BIOPHARMA. CANCER DRUG DELIVERY. ERKKI RUOSLAHTI, PH.D., PARTNERED THE PRECLINICAL PHASE OF ENDURX AND DRUGCENDR; A NANOPARTICLE-BASED DRUG DELIVERY TECHNOLOGY THAT CAN DELIVER A CANCER DRUG TO A TUMOR AND THROUGHOUT ITS TISSUE.
FORM 990, PART VI, LINE 11B	PROCESS USED BY MANAGEMENT AND/OR GOVERNING BODY TO REVIEW FORM 990 THE 990 IS PREPARED BY THE FINANCE DEPARTMENT. IT IS REVIEWED BY THE INSTITUTE'S TAX ADVISORS, SELECTED MEMBERS OF MANAGEMENT INCLUDING THE CFO AND AUDIT COMMITTEE AND PROVIDED TO MEMBERS OF THE BOARD PRIOR TO FILING.
FORM 990, PART VI, LINE 12C	DESCR OF PROCESS TO MONITOR TRANSACTIONS FOR CONFLICT OF INTEREST CONFLICT OF INTEREST STATEMENTS ARE GIVEN TO MANAGEMENT STAFF AND PRINCIPAL INVESTIGATORS ON A PERIODIC BASIS TO REPORT ON CONFLICTS OR LACK OF CONFLICTS. THE STATEMENTS ARE REVIEWED ANNUALLY BY THE SENIOR DIRECTOR, INTELLECTUAL PROPERTY AND THE SENIOR DIRECTOR, SPONSORED RESEARCH, WITH A SUMMARY OF THE REVIEW PROVIDED TO THE CFO. AN ASSESSMENT IS MADE AS TO WHETHER A CONFLICT CAN BE MANAGED BY THE EXISTING DEPARTMENTS AND PRACTICES. CONFLICTS ARE BROUGHT TO THE BOARD OF TRUSTEES ON AN AS NEEDED BASIS. CONFLICTS AND POTENTIAL CONFLICTS THAT INVOLVE THE CEO OR THE PRESIDENT ARE BROUGHT TO THE BOARD OF TRUSTEES TO ADDRESS ANY ACTUAL OR POTENTIAL POSSIBILITY THAT THE DESIGNATED REVIEWERS (I.E., SENIOR DIRECTOR, INTELLECTUAL PROPERTY AND THE SENIOR DIRECTOR, SPONSORED RESEARCH, AND THE CFO) COULD BE PRESSURED TO MAKE BIASED DECISIONS IN MANAGING CONFLICTS INVOLVING THE CEO OR PRESIDENT. AS TO RESTRICTIONS IMPOSED: THE INSTITUTE WILL EMPLOY THE MECHANISM THAT IS THE BEST FIT WITH THE FACTS AND CIRCUMSTANCES OF ANY IDENTIFIED CONFLICT OF INTEREST. METHODS TO MANAGE POTENTIAL CONFLICTS/ENFORCEMENT MECHANISM: REVIEWING MANAGEMENT IS RESPONSIBLE FOR MANAGING, REDUCING, OR ELIMINATING REAL OR POTENTIAL CONFLICTS OF INTEREST. EXAMPLES OF CONDITIONS OR RESTRICTIONS THAT MIGHT BE IMPOSED TO MANAGE, REDUCE, OR ELIMINATE CONFLICTS OF INTERESTS INCLUDE: -PUBLIC DISCLOSURE OF SIGNIFICANT FINANCIAL INTERESTS -MONITORING OF RESEARCH BY INDEPENDENT REVIEWERS -MODIFICATION OF THE RESEARCH PLAN -DISQUALIFICATION FROM PARTICIPATION IN THE PORTION OF FUNDED RESEARCH THAT COULD BE AFFECTED BY SIGNIFICANT FINANCIAL INTEREST -DIVESTITURE OF SIGNIFICANT FINANCIAL INTERESTS -SEVERANCE OF RELATIONSHIPS THAT CREATE ACTUAL OR POTENTIAL CONFLICTS -REVIEW OF COMMERCIAL SPONSORED RESEARCH AGREEMENTS FOR SCIENTIFIC MERIT BY THE PROGRAM PLANNING COMMITTEE -REMOVAL OF AN AFFECTED PARTY FROM NEGOTIATION WITH A COMPANY WITH WHICH HE/SHE HAS SIGNIFICANT FINANCIAL INTEREST.
FORM 990, PART VI, LINE 15A & 15B	PROCESS FOR DETERMINING COMPENSATION COMPENSATION FOR THE CEO, THE PRESIDENT, CHIEF FINANCIAL OFFICER, AND OTHER KEY EMPLOYEES IS ESTABLISHED ACCORDING TO INSTITUTE POLICIES WHICH ARE DESIGNED TO MEET THE IRS STANDARD FOR "REBUTTABLE PRESUMPTION OF REASONABLENESS". THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES, CONSISTING OF FOUR INDEPENDENT TRUSTEES, REVIEWS COMPARABILITY DATA PROVIDED BY AN INDEPENDENT EXTERNAL CONSULTANT THAT INCORPORATES AND EVALUATES INSTITUTE DATA AND THAT OF COMPARABLE ORGANIZATIONS AND MARKETS FROM WHICH THE INSTITUTE DRAWS ITS EXECUTIVE TALENT. UTILIZING THIS INFORMATION, THE COMPENSATION COMMITTEE, WHICH TYPICALLY SEEKS TO ESTABLISH COMPENSATION BETWEEN THE 50TH AND THE 75TH PERCENTILE OF THE COMPARABILITY DATA, MAKES A DETERMINATION WHETHER THE PROPOSED COMPENSATION IS REASONABLE. THE COMPENSATION COMMITTEE HAS BEEN DELEGATED AUTHORITY BY THE BOARD OF TRUSTEES TO REVIEW AND APPROVE COMPENSATION OF ALL POSITIONS EXCEPT FOR THE CEO. THE CEOS COMPENSATION PACKAGE IS REVIEWED AND APPROVED INITIALLY BY THE COMPENSATION COMMITTEE AND THEN GOES TO THE EXECUTIVE COMMITTEE FOR FINAL APPROVAL. THE COMPENSATION COMMITTEE CONTEMPORANEOUSLY AND ADEQUATELY DOCUMENTS THE BASIS FOR ITS DETERMINATION AND RECOMMENDATION TO THE EXECUTIVE COMMITTEE. IF APPROVED BY THE EXECUTIVE COMMITTEE, THE CEO COMPENSATION PACKAGE IS THEN IMPLEMENTED AND SUCH DOCUMENTATION IS KEPT IN THE WRITTEN AND ELECTRONIC RECORDS OF THE BOARD OF TRUSTEES. THE PROCESS WAS LAST COMPLETED ON JUNE 6, 2018 FOR THE FOLLOWING POSITIONS: 1) PRESIDENT 2) CFO 3) VP BUSINESS DEVELOPMENT 4) VP PHILANTHROPY 5) SVP DRUG DISCOVERY & DEVELOPMENT 6) CANCER CENTER DIRECTOR/PROFESSOR 7) INFECTIOUS & INFLAMMATORY DISEASE CENTER DIRECTOR/PROFESSOR
FORM 990, PART VI, LINE 19	PROCESS FOR MAKING DOCUMENTS AVAILABLE TO THE PUBLIC DOCUMENTS ARE AVAILABLE UPON REQUEST.
FORM 990, PART XI, LINE 9	OTHER CHANGES IN NET ASSETS OR FUND BALANCES RETURN OF STATE OF FLORIDA CONTRIBUTION RECEIVED IN PRIOR YEARS - ($10,888,000)

Schedule R IRS990ScheduleR

Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp

Disregarded Entity Name DisregardedEntityName

Field	Value	IRS element (for citing)
Business Name Line1	FL MED DISCOVERY INSTITUTE AT LAKE NONA	BusinessNameLine1Txt

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	10901 N TORREY PINES ROAD	AddressLine1Txt
City	LA JOLLA	CityNm
State Abbreviation	CA	StateAbbreviationCd
ZIP	92037	ZIPCd

Field	Value	IRS element (for citing)
EIN	474997825	EIN
Primary Activities	RESEARCH	PrimaryActivitiesTxt
Legal Domicile State	CA	LegalDomicileStateCd
Exempt Code Section	501(c)(3)	ExemptCodeSectionTxt
Public Charity Status	7	PublicCharityStatusTxt

Direct Controlling Entity Name DirectControllingEntityName

Field	Value	IRS element (for citing)
Business Name Line1	SBPMDI	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Controlled Organization	Yes (true)	ControlledOrganizationInd

Field	Value	IRS element (for citing)
Receipt Of Int Annts Rnts Rylts	false	ReceiptOfIntAnntsRntsRyltsInd
Gift Grnt Or Cap Contri To Oth Org	false	GiftGrntOrCapContriToOthOrgInd
Gift Grnt Cap Contri From Oth Org	false	GiftGrntCapContriFromOthOrgInd
Loans Or Guarantees To Other Org	false	LoansOrGuaranteesToOtherOrgInd
Loans Or Guarantees From Oth Org	false	LoansOrGuaranteesFromOthOrgInd
Div Related Organization	false	DivRelatedOrganizationInd
Asset Sale To Other Org	false	AssetSaleToOtherOrgInd
Asset Purchase From Other Org	false	AssetPurchaseFromOtherOrgInd
Asset Exchange	false	AssetExchangeInd
Rental Of Facilities To Oth Org	false	RentalOfFacilitiesToOthOrgInd
Rental Of Fclts From Oth Org	false	RentalOfFcltsFromOthOrgInd
Perform Of Services For Oth Org	false	PerformOfServicesForOthOrgInd
Perform Of Services By Other Org	false	PerformOfServicesByOtherOrgInd
Sharing Of Facilities	false	SharingOfFacilitiesInd
Paid Employees Sharing	false	PaidEmployeesSharingInd
Reimbursement Paid To Other Org	false	ReimbursementPaidToOtherOrgInd
Reimbursement Paid By Other Org	false	ReimbursementPaidByOtherOrgInd
Transfer To Other Org	false	TransferToOtherOrgInd
Transfer From Other Org	false	TransferFromOtherOrgInd